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Abstract
O nly EB V-in fected B lym phocytes which express the B cell
activation m arker CD23 are capable of estab lish ing im m orta lised cell
lines. Epste in-Barr v irus determ ined nuclear antigen 2 (EBNA-2) is 
essential for EBV-induced growth transformation (Cohen, et al, 1989) and 
can specifically upregulate CD23 gene expression (Wang, et al, 1987). The 
regulation of CD23 gene expression is likely to be an important factor in 
EBV-induced B cell growth transform ation. The ce llu lar CD23 prom oter 
and EBV TP-1 promoter have previously been shown to be transactivated 
by EBNA-2 (Wang, et al, 1991, Le Roux, et al, 1993). Studies have also 
shown that while EBNA-3A itself has no effect on the TP-1 promoter, it 
can repress EBNA-2-mediated transactivation in a B cell background (Le 
Roux, et al, 1994). Hom ologies have been shown between sequences 
present in the EBV TP-1 EBNA-2 responsive element and other functionally 
sim ilar sequences which are found in the CD23 prom oter region. The
purpose of th is study was to explore the regulation of CD23 gene 
expression by the EBV latent proteins EBNA-2 and EBNA-3A.
The most common reporter gene used in transfection studies is CAT 
(ch lo ra m p h e n ico l a ce ty l tra n s fe ra se ), u su a lly  assayed  using a 
radioisotopic method. To obviate the need to use a radioassay, an 
alternative reporter plasmid was constructed and tested in a range of cell 
backgrounds. This construct consisted of the CD23 prom oter cloned
upstream of the PAP gene (placental alkaline phosphatase). The assay 
involves a colorim etric reaction, and is a sim pler and cheaper reporter 
assay (Henthorn, et al, 1988).
In order to identify relevant sequence modules in the CD23 promoter, 
deletion mutants of CD23CAT were constructed for use in co-transfection 
assays with plasmids encoding EBNA-2/3A. A strategy based on using the 
nuclease BAL 31 was designed to create nested mutations. Fragments of 
the CD23 promoter including the EBNA-2 responsive elements were also 
amplified by PCR for cloning upstream of CAT.
1
C o-transfections were carried out using p lasm ids encoding the 
EBNA-2 and EBNA-3A proteins as well as the CD23 reporter plasmid. No 
PAP activity was seen in any of the samples containing the pCD23PAP 
construct. As the pCD23CAT plasmid produced CAT activity in DG75 (an 
EBV-negative B lymphoma cell line), it appears that the CD23 promoter is 
active in these cells and that the pCD23PAP construct is not functioning, 
or gives a low activity beyond the sensitivity of the enzyme assay. In a 
B cell background, the results indicate that EBNA-2 upregulates the 
activity of the CD23 promoter, increasing the amount of CAT activity by a
factor of 4-5. The EBNA-3A protein represses the EBNA-2-m ediated
upregulation of the CD23 promoter, with CAT activ ity returning to basal 
levels in the presence of both EBV proteins. A construct containing a 
deleted CD23 prom oter gave no basal CAT a c tiv ity  and was not 
transactiva ted by EBNA-2. This was as expected, as th is construct 
contains a deletion of approx. 200 bp which should remove the EBNA-2 
responsive sequence elements. Restriction analysis of the CD23 promoter 
sequence led to the identification of a novel Sma I site confirm ing the 
presence of a sequence change relative to the published CD23 sequence. 
These effects are not seen in other cell backgrounds. In conclusion, the
results of this study indicate that CD23 gene expression may be regulated
by the EBV latent proteins EBNA-2/3A in some cell backgrounds.
2
1. Introduction
1.1 EBV discovery and classification
Epstein-Barr virus is a ubiquitous human herpes virus that was first 
identified from studies by Denis Burkitt in the late 1950’s on an unusual 
childhood lymphoma of African children. He showed that the incidence of 
this lymphoma was determined by geographic factors and corresponded to 
the malaria belt in Africa, hence indicating an infectious origin (Burkitt, 
1962). This prompted the search for possible oncogenic viruses in tissue 
from what was to become known as Burkitt’s lymphoma (BL).
Attempts to infect newborn mice, em bryonated hen eggs and test 
tissue culture systems with BL m aterials in an e ffo rt to isolate virus
failed, as did electron m icroscopy studies. Based on experim ents with 
virus-induced animal tum our cells in culture, a search was made for an 
inapparent oncogenic virus in BL tissue by estab lish ing  long term 
continuous cell cultures from these materials.
In 1964, the ability to culture BL tumour cells in vitro  led to the 
establishm ent of a cell line (EB1) of continuously grow ing BL-derived 
lym phoblasts by the scien tis ts Epstein and Barr. They subsequently 
identified virus particles using electron m icroscopy in BL cells of African 
pa tien ts  (E pste in , et al, 1964). The virus was identified as a unique
herpesvirus as it did not react with antisera generated against known 
herpesvirus, and designated the Epstein-Barr virus. It seemed unusual that 
a member of the herpes family could be carried as an inapparent infection 
in a continuous human cell line without destroying the cultures. Ordinary 
biologic tests failed to identify the isolate so it appears EBV was the 
first viral agent discovered by electron m icroscopy alone. An association 
of EBV with another human cancer, Nasopharyngeal Carcinoma (NPC), was 
also discovered. This prompted a great deal of investigative work on EBV
as a potential model for cell control and cancer studies.
E pste in -B arr v irus  is c lass ified  as a m em ber of the genus 
lym phocryptovirus, which belongs to the subfam ily gam m aherpesvirinae 
(for review see (Power, et al, 1993)). EBV is a ubiquitous human herpes 
virus that is transm itted horizontally, infecting over 90% of all human 
populations. Following primary infection, whether sym ptom atic or silent,
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the virus persists in the healthy host for life by mechanisms that are not 
fu lly understood. In the western world EBV is largely associated with 
infectious m ononucleosis (IM) or g landular fever, a deb ilita ting  non- 
m alignant lym phopro life ra tive  syndrom e (Henle, et al, 1979). Infection is 
usually initiated in the oropharyngeal epithelium  which is perm issive for 
virus replication. Infection in the oropharynx is predom inately lytic, with 
complete replication of the virus linked to ordered squamous epithelia l 
d ifferentia tion. The continuous shedding of in fectious partic les in the 
saliva most likely results in the high rate of virus transmission by mouth 
to mouth contact.
In appropriate circumstances, EBV appears to contribute to several 
cancers, namely African endemic Burkitt’s Lymphoma (BL) of B cell origin, 
and anaplastic Nasopharyngeal Carcinom a (NPC) derived from poorly 
d iffe ren tia ted  ep ithe lia l ce lls  (K ie ff, et al, 1990, M agrath, 1990). In 
recent years there has been a dramatic increase in the reported incidence 
of E B V-associa ted non-H odgkins lym phom as in im m unosuppressed 
ind ividuals (Young, et al, 1989). Both transplant and AIDS patients have 
markedly increased risks of developing EBV-associated lymphomas. EBV is 
also associated with a fatal X-linked lym phoproliferation which occurs in 
congenitally im m unodeficient patients (Duncans syndrom e) (Mayer, et al, 
1994). Within such a huge natural pool of virus there exists the potential 
for extensive variation, but the extent of any such variability is not clear. 
Two strains, or types, of EBV infect humans-serotype A and serotype B. 
These strains differ in the sequences of the viral genes expressed during 
latent infection and in their ability to transform  B lymphocytes. Studies 
suggest that both stra ins are prevalent in the United States and that 
persons can be coinfected with both strains (Strauss, et al, 1993). The 
current view point is that there do not appear to be d isease-specific  
subtypes of EBV in that the ratio of A type to B type virus in EBV-related 
tum ours re flec ts  the p reva lence  of in fec tion  w ith in  the genera l 
population.
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1.2 General characteristics of herpesviruses.
The herpesviruses represent a very large, clearly defined group of 
viruses of considerable medical im portance and uniqueness. They are 
double-stranded DNA viruses, ranging in size from 100 kb to 240 kb and 
are divided into 3 subfamilies :
Fam ily C h a ra c te r is t ic s Site of 
la te n c y
Exam ple
a -he rp e sv irida e Rapid replication 
cycle < 24 hours 
Wide host range
Nerve
ganglions
Herpes Simplex
V iru s
(HSV 1&2)
p -he rpesv iridae Long replicative 
cyc le
Narrow host range
E p ith e lia l 
cells and 
lym phocytes
C ytom ega lo ­
v iru s
(CMV)
y-herpesv iridae B or T lymphocyte 
cell tropism
Lym phocytes E p s te in -B a rr 
virus (EBV)
The complex genome is composed of two unique sequence elements 
(unique short (US) and unique long (UL)), separated by internal repeats (IR) 
and bordered by terminal repeats (TR). The linear viral DNA is contained in 
an icosahedral protein capsid which is surrounded by an envelope derived 
prim arily from the nuclear membrane of the infected cell. The virion 
attaches to the cell surface via specific receptors. Fusion of the viral and 
cellu lar membranes allows liberation of the capsid into the cytoplasm. 
During m igration to the nucleus, the capsid is degraded and the 
nucleoprotein complex penetrates the nucleus. Viral DNA is transcribed by 
the cellu lar RNA polym erase II. Primary transcrip tion involves proteins 
implicated in replication e.g. thym idine kinase or DNA polym erase. In 
effect, the herpesvirus codes for a large part of its own replication, 
which follows the rolling circle model - concatamers of genomes linked in 
tandem are formed and subsequently cleaved at the term inal repeats. 
Capsid assembly occurs in the nucleus. The virions reach the cell surface 
via the endoplasmic reticulum.
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Herpesvirus infections are very widespread. Transm ission occurs via 
direct contact - by saliva, blood, sexual contact or from mother to child. 
Primary infection may not be accompanied by clin ical signs, but confers 
lasting immunity. Infection is said to be latent - a small number of genes 
is expressed and there is no viral production. Under certain conditions 
e.g. immunosuppression, reactivation can occur.
1.3 Diagnosis of EBV infection
Serodiagnosis of infectious m ononucleosis (IM) was established a 
long time before the discovery of its agent. In 1932 Paul and Bunnell 
described heterophile antibodies, a serologica l phenomenon associated 
with IM (Paul, et al, 1932). The so-called Paul-Bunnell reaction means an 
agglutination of erythrocytes from horse, sheep or cattle by the sera of 
patients with IM. These agglutination tests are now routinely used and are 
of low cost. Modern versions of this assay utilise purified Paul-Bunnell 
antigen coated (for example) on latex beads. However, the incidence of 
heterophile antibodies amongst IM patients is at most 90% and other 
diseases may provoke a heterophile antibody response. Testing for EBV- 
specific antibodies is therefore the preferred method fo r the serological 
diagnosis of IM.
Routine d iagnosis of EBV in fection is usua lly  carried  out by 
determining the level and class of antibodies to the various EBV antigens 
in a patients serum (fig. 1). These standard assays use fixed cells derived 
from various cell cultures infected with d istinct stra ins of EBV which 
express a particular viral antigen class (Henle, et al, 1971).
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A ntigen D e s c rip tio n
Viral capsid antigen 
(VCA)
Complex of protein 
constitu ting the viral 
nucleocapsid
Membrane antigen 
(MA)
Group of proteins present in 
or associated with the viral 
m em brane su rround ing  the 
nucleocapsid
-classified as early or late 
(EMA/LMA)
E ps te in -B a rr 
n u c le a r  a n tig e n s  
(EBNA)
V ira l p ro te in s  lo c a te d  
exclusively in the nucleus of 
EBV infected cells, of which 
there are at least six.
Early antigens 
(EA)- may be 
c lassified as 
diffuse (EA-D) 
or restricted (EA-R)
N on-structura l EBV prote ins 
p ro d u c e d  d u r in g  v ira l 
replicative cycle and by EBV 
undergoing reactivation.
Lym phocyte 
detected membrane 
antigens (LYDMA)
Vira lly encoded 
non-structura l membrane 
proteins located on 
the surface of EBV 
g ro w th -tra n s fo rm e d  
lym phocytes.
Most EBV antigens can be easily determ ined by d irect or indirect 
im m unofluoresence tes ts  (Henle, et al, 1974) except the viral nuclear 
antigens (EBNAs) which can only be detected by the more sensitive anti­
complement immunofluoresence method. Serology has played a major part 
in establishing a relationship between EBV and the major human diseases 
with which it is now firm ly associated.
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Figure 1. Time course of the serological response to the m ajor viral 
antigen classes after primary infection with EBV.
Several new techniques have been rapidly applied in recent years to 
the detection of EBV in clinical material. PCR has greatly improved the 
ability to detect low copy numbers (PCR will detect 1 or 2 target DNA 
sequences in - 1 0 ^ cells) (Joske, et al, 1993). The greatest lim itation of 
PCR is that it does not identify which cells are giving rise to a positive 
result. In lymphoma patients the question of whether their tumour cells 
are EBV DNA-positive is unanswerable by PCR as the signal may have come 
from other EBV-positive lymphocytes.
However, the PCR technique can be modified to detect “tumour- 
associated” EBV. In reverse transcription PCR (RT-PCR) the target to be 
amplified is not EBV DNA, but viral RNA transcripts. Primers for RT-PCR 
are designed that correspond to the EBV RNA transcrip ts expected in 
tumour cells. The resulting cDNA is subsequently amplified by PCR (Joske, 
et al, 1993).
In s itu  hyb rid isa tion  has a lso been used Two sm all non- 
polyadenylated EBV RNAs (EBER 1 and EBER 2) are produced during latent 
infection. These are transcribed by RNA polymerase III and are present in 
up to 107 copies per cell making them by far the most abundant viral RNA 
species and a good target sequence for in situ detection (Joske, et al,
1993).
1.4 Diseases associated with EBV infection.
Infectious m ononucleosis
The clearest causal role for EBV in human disease is in infectious 
mononucleosis (IM), the symptoms of which represent the course of the 
immune response to an EBV primary infection that has been delayed into 
adolescence or adulthood (Vousden, et at, 1994). The virus infects B 
lymphocytes but the mononucleosis is mainly of T lymphocytes which are 
responding to the EBV infected cells.
Primary EBV infections occurring in early childhood are normally 
silent or accompanied by such mild symptoms that IM is not usually 
diagnosed. With advancing age, as is the case with some other common 
viral illnesses, the severity of EBV primary infection increases. Infection 
la te r in pube rty  can resu lt in the d e b ilita tin g  non m a lignan t 
lymphoproliferative syndrome known as IM. C linically apparent IM tends 
to be a disease of econom ically advanced countries where a greater 
proportion of individuals escape infection in childhood, w ith the peak 
incidence of mononucleosis occurring in people 15 to 25 years of age. 
Individuals avoid contacting the virus until late adolescence when they 
begin dating (hence it is often called kissing disease).
Once a person has contracted IM, virus infected B-cells rapidly 
proliferate, provoking a characteristic cytotoxic T cell response, and take 
on an atypical appearance on blood film that is useful in diagnosis. The 
disease is manifested by enlargement of the lymph nodes and spleen, sore 
throat, nausea, general weakness and tiredness, and a mild fever that 
usually peaks in the early evening. The disease lasts for one to six weeks 
and is usually self-lim iting. A persistent active infection can sometimes 
ensue that continues at some level for many years (Strauss, 1988).
Patients in the acute phase of IM usually have a characteristic 
EBV- related antibody response. These patients have high titres of IgM and 
IgG antibodies to VCA and MA (which are structural proteins associated 
with EBV), they show a trans ien t anti EA-D (d iffuse early antigen) 
response in 85% of cases and no anti-EBNA ( Epstein-Barr nuclear antigen) 
as a rule. After convalescence, antibodies to EA-D disappear, while VCA, 
MA and EBNA antibodies persist over a lifetime, probably reflecting the 
persistent or in te rm itten t re lease of virus at low level. Anti-EBNA
antibodies arise gradually after several weeks or months (Henle, 1982). 
Since the early 1980's the EBNA's have been shown to consist of a family 
of at least six proteins. Following IM, antibodies to EBNA-2 appear first 
and after peaking, decline again in time to lower pers isten t or non- 
detectable levels. Antibodies to EBNA-1 have been shown to emerge 
several weeks or months after anti-EBNA-2 and gradua lly  a tta in  the 
levels at which they persist. The presence of IgG antibody to VCA 
indicates past infection and is thus an index of immunity to IM. Current 
infection is usually established by the presence of anti-VCA antibodies of 
the IgM type or by showing a rise in antibody titre to one of the several 
EBV antigen systems. Elevated and persistent anti-EA is likely to reflect 
an ongoing viral infection (Henle, et al, 1981).
EBV and carcinogenesis
There are 2 general stra teg ies whereby viruses are thought to 
contribute to carcinogenesis. In some cases expression of certain viral 
genes bypasses the need for one or more of the steps that would normally 
be involved in m ultistep carcinogenesis. The other general mechanism 
seems to involve the virus stabilising and promoting the growth of a cell 
population in which oncogenic genetic change may then occur (Vousden, e t 
al, 1994).
EBV has been closely linked to several cancers, including Burkitt’s 
lymphoma, Nasopharyngeal carcinoma, post transplant B-cell lymphoma, 
Hodgkins disease and AIDS-related lymphomas.
Burk itt’s Ivmphoma
Burk itt’s lymphoma is a poorly-d iffe rentia ted m alignant lymphoma 
that occurs sporadically throughout the world. There are however, high 
incidence areas, such as parts of equatorial East Africa and New Guinea 
(Burkitt, 1962). The m alignancy was firs t described by Denis Burkitt in 
the late 1950’s as a very aggressive tumour of the jaw  or ovaries and 
represents the most common childhood cancer in the tropics (up to 10 
cases per 10,000 per year) (Parkin, et al, 1984). Burkitt’s lymphoma is one 
of the fastest growing human tumours - it has a doubling time of about 24 
hours. Paradoxica lly  the ce lls are sm all but w ith a resting B cell 
phenotype. The pattern of EBV gene expression in Burkitt’s lymphoma is
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type I  latency : only EBERs (2 small non-polyadenylated RNAs) and EBNA-1 
are found (Joske, et al, 1993). The tumour cells carry very few activation 
molecules or vira l antigens (EBNA-1 is not a ta rge t fo r cyto toxic T 
lymphocytes) and hence may evade immune surveillance (Mayer, et al,
1994).
EBV genomes are present in the vast m ajority  of tumours from 
endemic areas. Some 96% of African cases have been shown to be EBV 
positive, com pared to 30% of sporadic cases in developed countries 
(Joske, et al, 1993). Furtherm ore, once the disease appears, Burkitt’s 
lymphoma patients have considerab ly higher (about 1 0 -fo ld) antibody 
titres to the EBV VCA and EA-R than do children w ithout the tumour 
(Lenoir, 1986). The high incidence of BL in the tropics is associated with 
geographic and clim atic features incident with holoendemic malaria. That 
m alaria in fection m ight be a co-factor in the developm ent of BL is 
supported by the observation that individuals with m alaria have reduced 
T-cell responses to EBV-infected cells (Whittle, et al, 1984).
The developm ent of both EBV and non-EBV-re la ted BL always 
involves the chromosomal translocation of one of the alleles of the c -m yc  
oncogene, (which encodes a ubiquitous phosphorylated nuclear protein that 
functions as a transcrip tional regulator contro lling ce llu la r proliferation, 
d iffe re n tia tio n  and apop tos is  (M arcu, et al, 1992)). This invo lves 
chrom osom e 8 and one of the 3 chrom osom es co n ta in ing  the 
immunoglobulin loci (chromosome 14 - heavy chain locus, chromosome 2 - 
k  light chain locus and chromosome 22 - X light chain locus)(Speck, 1987). 
The characteristic translocations are : t(2;8) (p12;q24), t(8 ; 14) (q24;q36), 
t(8 ;22) (q 2 4 ;q 1 1). These act to jux tapose  c - m y c  to one of the
immunoglobulin loci, normally active in B cells, with the result that this 
oncogene is constitutively active (Klein, 1985). The coding sequences and 
third exon of c - m y c  are always in tact desp ite  the considerab le  
variability of the translocation breakpoint in or around the gene.
In sporadic BL the breakpoint is norm ally at the switch region, 
consistent w ith this type of translocation aris ing in the lymph node 
germinal centre where isotype switching occurs. In endemic BLs however, 
the breakpoint on the immunoglobulin gene is usually at the J region or 
sometimes in the V or D regions, which would be consistent with the 
translocation occurring as a result of an error in VDJ jo in ing, which
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normally occurs in the bone marrow. So it seems that in the endemic areas 
in people w ith chronic m alaria, ce lls w ith th is type of translocation  
escape immune surveillance and other constraints and can become BL 
cells. Clonality of the cells and the EBV in them indicates that the virus 
infects early in the process and may well be in the cell when malignant 
transformation occurs. Very little is known about EBV in the bone marrow 
except that it can be transm itted by the bone marrow in a transplant 
(G ra tam a, et al, 1988). It is generally held that children in endemic areas 
have an enlarged pool of EBV-immortalised cells susceptib le to further 
genetic change (Joske, et al, 1993).
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma (NPC) is seen worldw ide, being rare 
among European and North Am erican Caucasians w ith age-ad justed 
incidence rates of less than 1 per 100,000 (Liebowitz, 1994). However, it 
occurs with a very high incidence in Southern China where it represents 
the most com mon tum our in m ales. NPC is derived from  poorly 
differentiated epithelia l cells and arises in the surface epithelium  of the 
posterior pharynx (Parkin, et al, 1984). Two strik ing features of this 
cancer are the constant detection of EBV genomes in NPC cells and the 
regular in filtra tion  of the tum our by non-m alignant lym phocytes. NPC 
occurs primarily in adults and is unlikely to be the result of primary EBV 
infection as it occurs in areas where initial EBV infection occurs during 
ch ildhood. The e tio log ic  fac to rs  iden tified  fo r NPC inc lude  EBV, 
environm ental risk factors (including the ingestion of sa lt-cured fish), 
and gene tic  su sce p tib ility , inc lud ing  a hum an leukocy te  an tigen 
(HLA)-associated risk as well as potentia l tum our suppressor genes 
located on chromosome 3 (Liebowitz, 1994).
Patients with NPC have elevated IgG antibodies to VCA and EA-D and 
this forms the basis of a screening test for the early detection of NPC in 
high incidence areas of China. A rising titre of IgA type antibodies to EA-D 
is a good diagnostic indicator of the onset of NPC, probably reflecting 
local antibody production in the pharynx (Henle, 1982).
The association between EBV and NPC was subsequently confirmed 
by EBV nucleic acid hybridisation studies on NPC biopsy material and by 
dem onstrating that EBV DNA was present in the NPC tum our cells
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(Liebowitz, 1994). Southern blot analysis has shown EBV DNA in NPC is 
c lonal, a ris ing  from  a s ing le  EB V-in fected ce ll. S tud ies invo lv ing  
immunohistochemistry, western immunoblotting and RT-PCR have shown 
that EBNA-1 is expressed in nearly all cases examined and that LMP-1 is 
expressed in approximately 2/3 of cases of EBV positive NPC. LMP-1 (EBV 
latent m em brane p ro te in -1 ) has profound grow th s tim u la to ry  effects 
in vitro and may exert sim ilar effects in the nasopharyngeal epithelium. 
As cells are stim ulated to divide, the presence of EBNA-1 ensures the 
viral genome will replicate and be distributed to progeny cells. LMP-2A 
and 2B mRNAs are also expressed, with LMP-2A being detected in most 
cases examined (Brooks, et al, 1992). EBNAs other than EBNA-1 have not 
been detected. They may not be important in EBV-mediated epithelial cell 
functions. A lternatively, the other EBNAs may be expressed in epithelial 
cells before the ir m alignant transform ation and may be downregulated 
after this event occurs. Further analysis of EBV gene expression in normal 
epithelia l cells and NPC cells may help resolve th is issue. A major 
problem  which has ham pered progress tow ards understand ing  the 
relationship between EBV and NPC has been the inability to culture cells 
from explanted tumours which are of epithelia l origin. In contrast with 
the association of an activated c-m yc  gene and BL, no cellular oncogene 
involvement with NPC has as yet been identified (Liebowitz, 1994).
EBV contribution to BL and NPC
It might be expected that a contribution of EBV to BL and NPC would 
be explained by the com bination of some of the vira l im m orta lisation
genes with oncogenic cell mutations, causing m alignant transformation. In
fact, most of these genes are not expressed in the tumour cells and the BL 
cell phenotype (as revealed by B cell surface markers) (Rowe, et al, 1987) 
is quite different from the LCL (lymphoblastoid cell line) cells where the 
virus is clearly causing the growth transform ation. The pattern of only 
EBNA-1 protein expression (Rowe, et al, 1987, Fahraeus, et al, 1988) is 
the minimum necessary to maintain the virus replication in the face of 
cytotoxic T cell-m ediated immune surveillance, d irected against epitopes 
from other im m ortalisation genes. This is not consistent, however, with 
complementation of oncogenic cell changes by EBV since no cell gene or 
process has yet been found to be transregulated by EBNA-1. Perhaps early
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in the development of the BL more of the immortalising genes might have 
been expressed. The tumour cells from EBV-positive BLs always retain the 
episomal EBV genome, suggesting that it is contributing to cell growth 
(Vousden, et al, 1994).
EBV and other Ivmphoproliferative neoplasia.
EBV is linked not only to BL and NPC but also to several 
lym phopro life ra tive  neop las ias in pa tien ts  w ith  innate  or acqu ired  
im m unode fic iency. A lack of h o s t-e ffe c tive  im m uno log ica l con tro l 
mechanism s of EBV replica tion in prim ary or pers is ten t in fection is 
considered crucial to the development of these diseases.
In X-linked lym phopro life ra tive  syndrom e (Duncans syndrom e) in 
males, a primary EBV infection is followed by a rapidly developing lethal 
disorder of im munoglobulin production or by a fa ta lly  progressing non- 
Hodgkins lymphoma (Mayer, et al, 1994). In recipients of organ transplant 
who undergo immunosuppressive therapy, most lym phoproliferations have 
a non-Hodgkins character, characterised by Type I I I  latency where all EBV 
latent genes are expressed. The tumours proliferate unchecked due to the 
absence of adequate T cell tum our suppressors. The tumours may be 
monoclonal or polyclonal. The incidence of EBV-positive lymphoma is 
approximately 2% after renal transplant, 5% after cardiac transplant, and 
1% or less for those receiving bone marrow (Joske, et al, 1993).
EBV has also been associated with Hodgkins disease, Type I I  latency 
being detected in Reed-Sternberg cells (characterised by the expression 
of EBER RNAs, EBNA-1, LMP-1 and the absence of EBNA-2) (Joske, et al, 
1993). Lymphomas are some 60 times more common in AIDS patients than 
in the general US population (Joske, et al, 1993).
The EB V -associa ted  lym phom as found in A ID S  pa tien ts  can be 
characterised as follows : B cell im m unoblastic lym phom as resembling 
p o s t-tra n sp lan t lym phom as, B u rk itt- like  lym phom a, p rim ary  cen tra l 
nervous system lymphoma, and Hodgkins lymphoma (Joske, et al, 1993).
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The patterns of EBV latent gene expression in all of the disorders 
have the follow ing sim ilarities :
(a) EBERs are expressed
(b) EBNA-1 is expressed
(c) All disorders may also arise without EBV
(d) EBV is present as a mono- or o ligo-clona l population (the EBV 
population has the same number of terminal repeats) i.e. either the virus 
was present in the cell when malignant conversion occurred or it imposed 
a malignant phenotype on the cell at a critical phase of differentiation.
1.5 Cell tropism
The host range for EBV is limited to humans and closely related 
primates and it has a narrow cell tropism, being restricted prim arily to 
B lymphocytes and epithelial cells. Type 2 com plem ent receptors CD21 
(CR2, C3dR) function as the main receptor for EBV on B lymphocytes and 
are carried on up to 10% of all B cells (Strauss, et al, 1993). CD21 is a 
membrane protein of 140 kDa. It is composed of three regions : a 34 amino 
acid cytoplasmic region, a 24 amino acid transmembrane domain and 15 to 
16 extracellular short repeat sequences (short consensus repeats - SCRs). 
The expression of CD21 dim inishes during the differentiation of B cells - 
the ability of EBV to infect the B cell correlates to the level of expression 
of its receptor (Nem erow , et al, 1990). The m ajor ou te r envelope 
glycoprotein is the EBV ligand for CD21. Upon infection, EBV can growth- 
transform and immortalise human peripheral blood B cells establishing a 
latent infection. “Latency” is the hallmark of herpesvirus infections and 
represents the con tinued  presence of v irus in in fected  ce lls  as 
autonom ously rep lica ting  episom es w ithou t the production  of v irus 
p a rtic le s .
In latent infection, virus penetrates the cell and remains present 
e ith e r as c irc u la r ep isom a l DNA (fo rm ed th rough  hom o logous 
recombination of the term inal repeat (TR) regions) or, less frequently, as 
linear DNA integrated into the host genome. Episomes, present in low copy 
number in the host cell nucleus, are copied by host cell DNA polymerase 
and passed to daughter cells in m itosis. This provides the basis for 
id e n tifica tio n  of m onoclona l EBV in a ce ll popu la tion  as each 
circularisation event results in a unique number of repeats in the TR
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region. Southern blot or PCR analysis of the length of a fused TR region, 
therefore, can be used to determ ine c lona lity  of cells derived from a 
single progenitor (Liebowitz, 1994).
Unlike other agents of B-cell activation, EBV does not induce the 
cells to te rm ina lly  d iffe rentia te ; rather, the in fected cells m aintain a 
blastoid state and proliferate perm anently (cell im m orta lisation). These 
cell lines are termed lymphoblastoid cell lines (LCLs) and express, as a 
marker, IgM on their surface. LCLs are considered to be immortalised but 
non-malignant cells as they do not form colonies in soft agar or tumours 
in nude mice (Mayer, et al, 1994). EBV-infected B lymphocytes express a 
number of B cell activation molecules, including CD23, CD30, CD39, CD40, 
CD44, and cellular adhesion molecules such as ICAM-1, LFA-1 and LFA-3 
(W ang , et al, 1990). Infection of B-lymphocytes with EBV is in fact the 
standard means today of establish ing human cell lines from specific  
donors. There are four main consequences of EBV infection in vivo :
(a) persistent antibody titres to viral antigens,
(b) interm ittent virus production from the oropharynx,
(c) estab lishm ent of v ira l latency in c ircu la ting  B lym phocytes, and
(d) T -ce ll dependent ce llu la r im m un ity  d irec ted  to v iru s -in fe c te d  
B -lym phocytes.
Virus-induced cell-growth transformation appears to be achieved through 
the action of a lim ited set of viral proteins, the "latent" EBV gene 
products.
1.6 Epithelial cell infection
Epithelial cell infection is a critica l event in the developm ent of 
NPC and oral hairy leukoplakia of the tongue, a second EBV-associated 
ep ithe lia l ce ll p ro life ra tio n  which is seen in im m unocom prom ised 
patients. Only some primary epithelial cells express CD21, few have been 
successfully infected with EBV and none has survived the infection. A 
recent study has provided evidence that antibody to EBV assists entry into 
certa in  ep ithe lia l ce lls  (Sugden, 1992). Both NPC and oral hairy 
leukoplakia patients express anti-EBV IgA-type antibodies which are of 
predictive value in diagnosis.
Most people infected with EBV mount a vigorous humoral immune 
response to the viral antigens which does not include IgA-type antibodies 
(S ixbey, et al, 1992). Some polarised epithelial cells display receptors for 
polym eric IgA (plgA). PlgA can bind this receptor, enter the cell, be 
modified and released from the opposite face of the cell (fig. 2 ).
Mucosal epithelial cells
IgA bound to 
secretory 
component 
and secreted 
into luminal 
space
receptor
Figure 2. Antibody-assisted entry of EBV.
In cell culture, EBV binding by specific anti-EBV plgA molecules has been 
shown to mediate entry of EBV into an established human epithelial cell 
line that expresses the receptor for plgA. This is a worrying prospect 
considering that potential vaccines may induce an IgA response to EBV 
antigens.
Study of EBV because of the nature of latent infection w ithout ways 
to produce large quantities of virus particles, and because its target cell 
is hard to culture, has relied largely on the use of recom binant DNA 
technology - including cloning and sequencing the genome.
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1.7 Molecular biology of EBV
Interest in the m olecular biology of EBV has prim arily  centred 
around three areas. These are (1) its ab ility  to im m orta lise  human 
B-lymphocytes in culture, (2) the mechanism of its ab ility  to persist in 
infected individuals, and (3) as a relatively com plex system in which to 
study gene regulation in human cells. An infectious centre assay for EBV 
does not exist however, and this has hampered the application of many 
methods of genetic analysis to this virus.
The EBV genome is a double stranded DNA molecule of approx. 170 kb 
that encodes over 80 prote ins (Speck, 1987) and exists as a linear 
molecule in the viral capsid. Upon infection, EBV circularises and resides 
largely as a free episome in the nucleus of infected cells (Speck, 1987). 
The viral genome is composed of both unique and repetitive sequences. At 
either end of the genome there are variable numbers of direct term inal 
repeats involved in virus circu larisation. The major internal repeat IR1 
towards the left end of the genome is composed of d ifferent numbers 
(strain dependent) of 3.2 kb repeats, with each repeat sequence containing 
one Bam HI site. Between the repeats lie the unique long (UL) and unique 
short (US) regions (fig. 3).
Tandem ly repeated sequence elem ents occur w ith in m ajor open 
reading frames - reflected in many cases as repeated amino acid patterns 
e.g. a variable number of a 700 bp repeat in EBNA-1 gives rise to the 
antigenic repeats (G ly,G ly,A la). In some cases the repeat unit may be 
spliced out of the mRNA.
The prototype strain of EBV, B95-8, has been completely sequenced 
(B aer, e ta !, 1984). This is an IM isolate able to enhance the growth of 
lymphocytes and express nuclear antigen. However, a deletion in B95-8 
relative to most strains has been characterised at the DNA sequence level.
During latent in fection of B cells in cu lture only 9 EBV latent 
proteins are made. These include the six EBV nuclear antigens (EBNAs- 
1,2,3A,3B,3C,LP), and three latent membrane proteins (LMP-1, LMP-2A 
(also called TP1) and LMP-2B (or TP2)) (Kieff, et at, 1990). The Epstein- 
Barr encoded RNAs (EBERs) are also produced during latent infection and 
are by far the most abundant viral RNA species (up to 107 copies per cell).
The EBERs are likely to play a role in rescuing infected cells from virus- 
induced translational arrest, an effect which is known to be interferon- 
induced (Bhat, et al, 1985).
The production of infectious virions requires the expression of many 
other genes that encode structural components of the virus (VCA and MA) 
and other proteins which are essential for viral lytic cycle replication and 
virion assembly. The expression of the EBV BZLF1 immediate early gene - 
ZEBRA (Z EBV replication activator) acts as the switch that triggers viral 
replication in latently infected B cells (Strauss, et al, 1993). This protein 
also transactivates expression of other immediate early genes as well as 
the expression of ZEBRA itself. These genes, in turn, upregulate the 
expression of early gene products, which include the viral DNA polymerase 
and thymidine kinase, important for DNA replication. Finally, the late gene 
products are made, including structural components of the virion such as 
the VCA, and gp350 which is the major envelope glycoprotein of the virus. 
Recent studies have led to the identification of an EBV protein that has an 
extensive homology with human interleukin -10  and it has been shown that 
both proteins share several properties (Vieira, et al, 1992). By inhibiting 
T cell growth and y-interferon production, “Epste in-Barr v ira l in terleukin- 
10” may lim it host responses directed at e lim inating the virus. In this 
regard, EBV may have captured a cellular gene that aids its survival.
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Figure 3 : Schematic representation of the EBV genome. 
A : The principal regions of the genome.
US -short unique region
IR -internal repeat (5-12 copies of 3072 bp)
UL -long unique region
TR -terminal repeat (1-20 copies of 500bp)
B : The Bam HI restriction map.
1.8 Genes involved in immortalisation
Much attention has been given to this restricted set of viral proteins 
known as ‘latent proteins’ as they are essential for B cell transformation 
and for the control of latency itself (Sugden, 1989).
EBNA-1
The EBNAs play im portant roles in the m odulation of v ira l and 
cellular gene expression. EBNA-1 is required both for latent replication of 
the EBV genome and as a regulator of viral gene transcription (Speck, 
1987, Sugden, 1989). EBNA-1 is encoded in a 2kb open reading frame 
mapping to the left end of the viral Bam HI K fragment and contains the 
IR3 repeat. This gives rise to a polypeptide of about 70 kDa (varies among 
strains), approx. 2 0 0  residues of which are composed of an irregular 
co-polymer of glycine and alanine, the remainder being rich in arginine and 
proline (Speck, 1987).
EBNA-1 is present in all lymphoblastoid and BL cell lines examined 
(Speck, 1987). A cloned region of the Bam HI C fragment functions as the 
replication orig in for maintenance of v ira l genomes (ori-P) in la tently 
infected cells only when EBNA-1 is present. This function appears sim ilar 
to the SV40 large T antigen (Speck, 1987). The state of latent infection is 
maintained by the EBNA-1 protein; it binds to ori-P allow ing the viral 
genome to be m aintained in the nucleus of the B cell (Sugden, 1989, 
Strauss, et at, 1993).
EBNA-2
EBNA-2 is encoded by a 1.5 kb open reading frame (BYRF-1) spanning 
the junction between Bam HI Y and H fragments. There are 2 serologically 
distinct forms of EBNA-2 due to divergent genomic sequences in BYRF-1 
(EBNA-2A and EBNA-2B) whose antigenic properties allow typing of the 
virus into Type A and Type B. The naturally occuring mutant virus P3HR-1 
which cannot transform  cord blood lym phocytes conta ins a deletion 
spanning the EBNA-2 coding region. This deletion is responsible for the 
mutant phenotype of P3HR-1 (Allday, et al, 1994). Superinfection of the 
EBV positive BL cell line Raji with P3HR-1 virus results in recovery of 
recom binant im m orta lis ing viruses
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Two of the EBV latent genes encode proteins that transactivate other
viral genes. W hile EBNA-1 transactiva tes the EBNA genes, EBNA-2
transactivates the expression of 2 EBV latent membrane proteins, LMP-1 
and LMP2. EBNA-2 is essen tia l (but not su ffic ie n t) fo r ce llu la r
im m orta lisation to occur (Ham m erschm idt, et al, 1989) and is involved in 
regulating the activities of both cellu lar and viral genes. Cellu lar genes 
whose expression is upregulated by EBNA-2 include the two B cell surface 
antigens CD23 and CD21 (Suter, et al, 1987, Wang, et al, 1987, Cordier, et 
al, 1990, Aman, et al, 1990) and also the c -fg r  proto-oncogene (Wang, e t 
al, 1990, Knutson, 1990) (the EBNA-2A prote in transactiva tes  more
effic iently than EBNA-2B (Cordier, et al, 1990)). EBNA-2 has an acidic 
transactivating domain at its C term inus (amino acids 426 to 483) which 
is functionally sim ilar to that of another herpesvirus acid ic transactivator 
VP16 (Tong, et al, 1995). Expression of EBNA-2 in Rat-1 cells affects the 
serum requirements of the cells and induces increased levels of CD23 cell 
surface antigen expression in an EBV negative human B cell line (Wang, e t 
al, 1987). CD23 is the human Fc e receptor lla  and expression is increased 
by exposure to IL-4. Some an tibod ies to CD23/FceR II s tim u la te  a 
proliferation response in uninfected B cells (Gordon, 1989). The CD23 
molecule has itself been shown to be intimately involved in a pathway of 
autocrine growth stim ulation (the functions of this molecule are reviewed 
in greater detail later in this text). The secreted form of CD23 may be a B 
cell growth factor, but the full length molecule may be a receptor, thus 
providing autocrine stim ulation of EBV infected B cells (Strauss, et al,
1993). Hence EBV can induce B cells to accumulate an IL-4 responsive 
surface antigen that is involved in cellu lar proliferation. EBNA-2 has also 
been shown to activate the genes which encode the latent membrane 
proteins (Wang, et al, 1990, Z im ber-Strobl, et al, 1991). The expression of 
a reporter gene under the control of the HIV LTR (long terminal repeat) has 
also been shown to be increased by EBNA-2 (Scala, et al, 1993). 
Transfection of an EBV-negative cell line with a plasmid encoding EBNA-2 
confers resistance to the anti-pro liferative effect of a -in te rfe ro n  (IFN -a) 
(Aman, et al, 1990).
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EBNA-3A/3B/3C.
EBNA-3A and EBNA-3B are encoded by genes which have been 
mapped to the Bam Hl-E region of the EBV genome. The EBNA3 transcripts 
have been shown to be rightward in direction, with each containing short 
and long open reading frames joined together by splicing to form the long 
open reading frames encoding each protein (Kerdiles, et al, 1990). These 
proteins are sim ilar in structure, sequence and size. They are composed 
respectively of 944, 938 and 992 amino acids, with m olecular weights 
from 145 kDa, to 165 kDa and are rich in proline residues. Antigenic 
variations of the EBNA-3 proteins between viral strains are not as marked 
as for EBNA-2 (comparison of sequences of each of the EBNA3 proteins 
from strains B95-8 and AG876 show homologies from 72% to 90%). These 
varia tions are probably not im portant for im m orta lisa tion  or for cell 
growth (Sample, et al, 1990).
No precise functions have as yet been described for EBNA-3A/B/C. 
Structural sim ilarities of these proteins suggest that they may have one or 
more identical functions. Stable transfection of EBNA-3C into the EBV 
positive cell line Raji (where EBNA-3C is not functiona l) results in 
increased expression of LMP-1 and CD21 (Allday, et al, 1994, Wang, et al,
1990). Recently it has been shown that the stable expression of EBNA-3B 
in a cell line derived from the EBV negative B cell line DG75 stimulates the 
expression of the B cell activa tion m arker CD40 and represses the 
expression of the d ifferentia tion antigen CD77/BLA (S ilins, et al, 1994). 
Since EBNA-3 proteins exhib it DNA-binding capab ility  in crude protein 
extracts  from  E B V -transfo rm ed ce ll lines, and EBNA-3C conta ins 
sequences homologous to a basic leucine zipper motif found in one class of 
mammalian transcrip tion  factors, it is like ly EBNA-3C functions as a 
transcrip tion activa to r (Sam ple, et al, 1994). The EBNA-3 proteins have 
recently been shown to repress the EBNA-2 mediated transactivation of 
viral and cellular genes in vitro (Le Roux, et al, 1994). Hence this group of 
proteins is implicated in the regulation of gene expression of EBV-infected 
B lymphocytes. Construction of EBV recombinants has shown the proteins 
do not have the same importance in the immortalisation process : EBNA-3A 
and EBNA-3C are necessary, while EBNA-3B can be deleted w ithout any 
effect to the immortalisation power of the virus (Tomkinson, et al, 1993).
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The EBV latent membrane proteins appear to play an important role in 
cellu lar transform ation. LMP-1 is encoded by the open reading frame 
BNLF1. It is composed of 386 amino acids and its molecular weight varies 
from 58 and 63 kDa depending on the viral strain. It has been shown to act 
as a direct oncogene in transformation assays (Baichail, et al, 1989). It is 
also a potent stimulator of phenotypic changes in B lymphocytes (Wang, e t 
al, 1990, Sugden, 1992). These latter effects include stim ulation of the 
expression of several leukocyte in terce llu lar adhesion m olecules (LFA-1, 
LFA-3 and ICAM-1) and the transferrin receptor, all of which are known 
to contribute to B cell growth regulation (Peng, et al, 1993). Expression of 
LMP-1 in ep ithe lia l cells transform s them m orpho log ica lly , and in B 
lymphoma cells LMP-1 prevents program m ed cell death or apoptosis. 
Genetic analyses using viral mutants indicate that EBNA-2 and LMP-1 are 
essential for transform ation.
By associa ting  w ith the in term edia te  filam ent pro te in  v im entin , 
LMP-1 is like ly to be involved in calcium channelling, an activ ity which 
leads to the transduc tion  of s ig na ls  w ith re levance  to ce llu la r 
proliferation (Hammerschm idt, et al, 1989). Recent evidence suggests that 
LMP-1 promotes the survival of its host B cell by a mechanism which 
allows it to gain direct access to the long-lived memory B-cell pool.
LMP-2A and LMP-2B
LMP-2A and LMP-2B are likely to interact with the LMP-1 as all three 
proteins are known to co-localise in the lym phocyte plasm a membrane 
(Longnecke r, et al, 1990). They are composed of 9 exons - one from the 
BamHIA fragment of the genome, and 8 from the Bam Hl-Nhet fragment. The 
genome must be circular for expression of these proteins as some of the 
exons are in part located in the region containing the TR. Evidence suggests 
an important role for LMP-2A/2B in EBV-related malignancies : the LMP-2A 
gene has been shown to be expressed in uncultured Burkitts lymphoma cells 
(Parkin, et al, 1984) and LMP transcripts have also been recently described 
in a majority of NPC specimens (Busson, et al, 1992).
LMP-1
Thus transformation of B cells is a complex process that involves the 
function of several EBV gene products to maintain the viral genome in the 
cell, transactivate viral and ce llu lar gene products im portant for B cell 
growth, and prevent apoptosis.
1.9 Viral transcription in latent infection
Producer cell lines e.g. B95-8 have almost the entire viral genome 
represented at some level in cytoplasm ic poly A+ mRNA, whereas non­
producer strains e.g. Raji, show only 5% of the genome represented as 
polysomal mRNA. In either case the most abundant transcripts are 2 small 
RNA Pol-Ill products encoded at the left end of the Bam-HI C fragment 
(Epstein-Barr encoded RNAs - EBERs). These have been located in the 
nuclei of in fected cells by in situ hybrid isation (Speck, 1987). The 
transcription of all EBV genes except EBERs is mediated by the host 
cellular RNA polymerase II with most EBV promoters functioning in vitro 
with an RNA polymerase II system and displaying no unusual functions.
All of the viral messages except the transcripts encoding the two 
forms of the latent membrane protein LMP-2A/B are transcribed from left 
to right (Speck, 1987). Transcription of LMP-1 is driven by a specific 
prom oter (Fennewald, et al, 1984) located in a 3 kb region at the extreme 
right of the vira l genome. This prom oter is b id irectiona l, also driving 
transcrip tion of LMP-2A/B (Laux, et al, 1989). The circularisation of the 
viral genome is necessary for the synthesis of the LMP-2A/B proteins, as 
they contain exons situated in the TR region.
The EBNAs are all translated from a group of related mRNAs which 
are form ed by the alternate sp lic ing and 3 ’ processing of a primary 
transcript that is >100 kb long. These mRNAs all share long 5 ’ leaders that 
are assembled by multiple splicing events and joined to 3’ coding regions 
that are unique to each EBNA. The leader sequences are composed of 
multiple repeating units of two small exons which orig inate from within 
the viral long internal repeat sequence (IR1) (Walls, et al, 1991).
Transcrip tion of the EBNAs is d irected by two prom oters : Wp 
(BW-R1) (Sample, et al, 1986) and Cp (BC-R2) (Bodescot, et al, 1987). Wp 
is located in the IR1 region of the genome - hence there are multiple 
copies of this promoter. It is more active than Cp - activity is stimulated
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by binding of EBNA-1 to OriP (Sugden, et at, 1989). Im m ediately after 
infection, Wp directs synthesis of the EBNAs, followed by a switch to Cp 
in favour of Wp under the influence of EBNA-2 (W oisetschlaeger, et at,
1989).
In the case of Type I  or I I  latency where EBNA-1 is the only protein 
expressed, transcription is driven by a different prom oter : Fp, which is
situated in the BamHI-F region of the genome (Sample, et al, 1991). In this
case EBNA-1 has a negative regulatory effect on the activ ity  of this 
promoter (Sample, et al, 1992).
1.10 Immunological considerations
Norm al or m a lignan t B lym phocytes w h ich  have not fu lly  
d iffe ren tia ted  to plasm a ce lls  are susceptib le  to v irus  penetra tion,
adsorption and establishm ent of latency. The population of infected B 
cells produces an EBV specified surface antigen LMA (latent membrane 
antigen) which is recognised by the cellular immune system. Immediately 
after primary infection, EBV-carrying B cells m ultip ly rapidly. The initial
advantage of host cell expansion may become a disadvantage to the virus 
as the processed derivatives of some EBV latent proteins have been shown 
to serve as targets for cytotoxic T cells (CTLs). All healthy EBV-carrying 
individuals are known to possess potent v irus-specific  CTLs which will 
control the expanding virus-in fected B cell population (R ickinson, 1990, 
Tosato, 1987).
Activated immunoblasts may also respond to non-immune feedback 
controls that protect the host from over-expansion of stim ulated B cell 
clones (Klein, 1989). Immune suppressed individuals will occasionally be 
unable to contain the population of infected B cells and will go on to 
develop lymphomas. It seems like ly the reactivation of la tent virus is 
re la ted  to the  d e ve lo p m e n t of som e of the  E B V -a ssoc ia ted  
lym phoproliferative disorders seen in AIDS patients.
It has now come to light that such T cell responses are rarely if ever 
directed against epitopes derived from EBNA-1, but are preferentia lly  
directed against the o ther la tent prote ins (M urray, et al, 1990). The 
restricted expression of EBV latent genes together w ith the associated 
eclipsing of cellu lar adhesion molecules enables such virus-infected cells
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to evade T-cell im m unosurveillance. However, in B-cell lym phom as of 
immunosuppressed patients, the tumour cells express a full set of EBV 
latent proteins as well as the cellu lar adhesion m olecules that bind T 
ce lls .
These cells probably grow in an uncontrolled fashion because the 
immune system  is defective. In BL, however, a host-ce ll-dependent 
difference in viral gene regulation means that EBNA-1 is the only latent 
protein to be expressed due to a difference in the state of viral DNA 
methylation (Cedar, 1988). EBNA-1 is the only protein which is expressed 
independently of host cell phenotype, presumably due to it’s essential role 
in replicating the genome. It now seems that EBV is maintained in a type 
of small resting B cell that only expresses EBNA-1 as the sole viral 
protein and does not express the ce llu la r m olecu les needed fo r 
interactions with cytotoxic cells.
1.11 Avoiding apoptosis
Protection from apoptosis is conferred through expression of a 
single EBV la tent protein LMP-1 by up-regu la ting expression of the 
ce llu la r oncogene bcl-2  (H enderson, et al, 1991). Bcl-2  is a strong 
repressor of programmed cell death in lymphocytes. Its dominant role as 
an apoptosis regulating gene is reflected in the w ide d istribution  of 
expression of bcl-2  in d iffe rent cellu lar systems as well as d ifferent 
species (Delia, et al, 1992, Garcia, et al, 1992). The bc l-2  proto-oncogene 
is a h ighly expressed gene located on chrom osom e 18 next to the 
b reakpo in t of the t( 14; 18) tra n s lo ca tio n  of fo llic u la r  lym phom as 
( F in k e ,  et al, 1994). A lthough not tum orig en ic  by itse lf, b c l - 2  
collaborates with other oncogenes such as myc by preventing apoptosis 
(Fanidi, et al, 1992).
Recent evidence suggests that persistence is based on the long term 
survival of individual B cells within the recirculating memory B cell pool 
(Yao, et al, 1989). However, entry into memory is normally restricted to a 
very small proportion of the total numbers of B cells generated in vivo 
and depends on positive selection in germinal centres, where all B cells 
are programmed to die by apoptosis unless rescued into the long lived pool 
by virtue of high affin ity antigen binding (Liu, et al, 1989). The m ajority 
of germ inal centre B cells are b c l-2 - r \e gative  and recen t ev idence
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suggests that m emory cell se lection involves upregu la tion  of b c l - 2  
(P ezze lla , et al, 1990). Hence virus-infected B cells have the potential to 
bypass physiological selection in vivo and gain direct access to the long 
lived memory B cell pool by b c l-2  upregulation by the expression of 
LMP-1 (Henderson, et al, 1991).
EBV-im m ortalised cells undergo several phenotyp ic changes that 
facilitate im m ortalisation. One im portant change is the establishm ent of 
an autocrine loop where the EBV infected B cells produce growth factors 
that s tim u la te  the ir p ro life ra tion  (S trauss, et al, 1993). Early in the 
course of acute IM, activated cytotoxic T cells are found in the peripheral 
b lood. A m inority of virus-carrying cells may avoid immune restraints by 
dow nregulation of EBNA-2 and associated eclipse of the activa tion  
markers. BL cells expressing only CALLA, BLA and EBNA-1 but not EBNAs 
3A/3B/3C/LP or any of the immunoblast markers represent the neoplastic 
counterpart of la tently  in fected normal B cells w ith a corresponding 
phenotype. As long as they remain in Go such cells would escape rejection 
by the immune system. The small heavy lym phocytes of normal healthy 
individuals that can grow directly into cell lines are consistent with the 
expected phenotype. The LCLs represent the most likely counterpart of the 
EBV-transformed B blasts that proliferate in in fectious m ononucleosis, 
whereas BL cells are more like resting cells although they are not in Go- 
LCLs are also more sensitive than BL cells to CD8 +CTLs generated by 
repeated stimulation with autologous EBV-transformed LCLs. Such T cells 
kill LCLs in an MHC class I  restricted fashion. BL cells derived from the 
same donor are usually resistant as long as they m aintain the BL 
phenotype, but tend to become sensitive as they change to a more 
immunoblastic LCL-like cell (Khanna, et al, 1995).
Three phenotypic tra its  are associated with the resistance of BL 
cells to CTLs. First BL cells do not express the potentially immunogenic 
EBNA 3A/3B/3C/LP and LMP products. Second, both EBV-carrying and EBV- 
negative BL ce lls  dow nregu la te  certa in  HLA class I  p o lym o rp h ic  
determ inants relative to the corresponding LCLs and hence are less 
sensitive to ordinary a llospecific  CTLs directed against MHC class I 
antigens. Thirdly, BL cells express certain cell adhesion molecules at a 
lower level than the correspond ing  LCLs. The consis tence  of the 
downregulation of the 3 tra its  m entioned makes it like ly  that they
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represent phenotypic vestiges of the normal p recursor cell. The cell 
phenotype-dependent downregulation of EBV in BL cells would then reflect 
the adaptation of the virus to persist in a la tent im m unologically non- 
recognisable form in a normal cell that tends to escape immune rejection 
for other reasons (Khanna, et al, 1995).
Previously BL, LCL and NPC cells were believed to express the same 
set of v ira lly  encoded “grow th transfo rm ation  assoc ia ted  p ro te ins ” . 
Recent studies have shown differential gene expression in the three cell 
types (Klein, 1989). EBNA-1 is the only prote in which is expressed 
independently of host cell phenotype, presumably due to it's essential role 
in replicating the viral genome. EBNA-2 is expressed in LCL cells but not 
in BL or NPC. Downregulation of gene expression is associated with DNA 
methylation. There are a small m inority of BL EBNA-2 defective viruses 
but most carry intact EBNA-2 genes that are not expressed. Evidence 
suggests downregulation of EBNA 3A,3B,3C and LP sim ilarly to EBNA-2 in 
BL and probably in NPC as well. LMP is expressed in LCL and downregulated 
in type 1 BL like EBNA-2. NPC biopsies express LMP in about 50% of 
tumours (Liebowitz, 1994).
1.12 Where is the reservoir of EBV ?
Following primary infection the virus persists in the healthy host 
for life. Since virus replication destroys epithe lia l cells, and yet virus 
excretion continues for years, EBV infection of cells in the oropharynx 
would have to be low grade, coursing asynchronously from cell to cell 
with time for uninfected epithelia l cells to regenerate and differentiate. 
The detection of EBV genomes in oropharyngeal and salivary epithelial 
cells has supported this view. However, most recent studies favour the 
concept of virus carriage in the lymphoid com partment via the long term 
survival of non-productively infected B cells (Gratama, et al, 1988, Yao, 
et al, 1989). New findings with bone marrow transplant recipients support 
this view. Bone marrow transplantation has been shown to eradicate the 
resident EBV population if the marrow donor is seronegative. If the donor 
is seropositive, the donors virus can replace that of the recipient. The 
eradication of the resident virus suggests the latent virus is harboured in 
a tissue com partment destroyed by the treatm ent and replaced by the 
graft, ind icating that the vira l reservoir responsib le fo r life long EBV
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persistence is the hem opoie tic com partm ent (K le in , 1989). Evidence 
suggests that long lived resting B cells in Go may carry at least part of 
the latent viral genomes in healthy EBV seropositives (Lewin, et al, 1990).
1.13 Vaccines and therapy
The magnitude and variety of clinical problems posed by EBV-linked 
neoplasia justify the efforts aimed at developing an effective vaccine. At 
present there is no EBV vaccine available for use in humans. Because a 
live EBV vaccine, how ever attenuated, could reta in  it's  oncogenic 
potential, research is being concentrated on a subunit vaccine or an 
inactivated virus vaccine. The goal has been to develop vaccines that 
confer high levels of specific virus-neutralising protective antibodies and 
thereby prevent EBV from attaching to susceptible cells. Components of 
the EBV MA are known to have potential as candidate im munogens 
(Rickinson, 1990). Research has concentrated on use of the EBV gp350 
envelope glycoprotein, which binds to the known virus receptor on B cells. 
Gp350 elicits a cellu lar immune response and CD4-positive T cell clones 
from infected humans recognise epitopes on gp350. The best results so far 
have been achieved in a primate model using purified gp350 incorporated 
in to  im m u n o s tim u la to ry  co m p le xe s  and a d m in is te re d  w ith  an 
im m unoad juvant. A fte r EBV cha llenge , a p ro te c tio n  aga in s t the 
development of lymphomas was observed in vaccinated animals (Morgan, 
et al, 1988). Despite the progress made in this area there remain several 
obstacles to vaccine production. Concern exists that the vaccine-induced 
immunity would wane and merely delay the age of prim ary infection, 
hence making infection worse, or that the vaccine would not protect 
against infection by a natural route. Serum from humans infected with 
EBV contains antibodies to gp350 antigens. In addition most people have 
salivary IgA antibodies to gp350, suggesting such antibodies are unlikely 
to be the basis of long-term immunity in healthy seropositive individuals. 
It seems unlikely that a vaccine based solely on gp350 will be completely 
effective in preventing infection; however it may have the potential to 
significantly reduce the load of infectious virus and thus lim it the long- 
lived EBV-positive B cell pool (Khanna, et al, 1995). There is still a long 
way to go before routine vaccination becomes a way to guard against EBV 
in fe c tio n s .
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Reactivation of EBV after bone marrow transp lanta tion  leads in 
many cases to lym phopro life ra tive  d isease tha t responds poorly to 
standard therapy and is usua lly fa ta l. To p revent or con tro l th is 
com plication, recently EBV-specific cytotoxic T lym phocyte (CTL) lines 
have been prepared from donor leukocytes and infused into a llograft 
re c ip ie n ts  (R o o n e y , et al, 1995). In the three patien ts w ith EBV 
reactivation, EBV DNA concentra tions (m easured by sem i-quantita tive  
PCR), which had increased 1000-fold or more, returned to the control 
range within 3-4 weeks of immunotherapy. It appears that EBV-specific 
donor-type T cell lines may offer a safe and effective therapy for the 
control of EBV-associated lym phoproliferation.
1.14 Regulation of CD23 gene expression by EBV.
The B cell activation marker CD23 has been closely associated with 
EBV infection, being h ighly induced in EBV in fected B lym phocytes. 
However, it is also expressed after B cell activation by antigen, mitogen, 
or IL-4 stimulation. CD23 is closely associated with an EBV immortalising 
function, since infection w ith the EBV non-transform ing virus P3HR-1 
does not induce CD23, and only EBV infected B lymphocytes which express 
CD23 are capable of establish ing im m orta lised cell lines. EBNA-2 is 
essential for EBV-induced growth transformation (Cohen, et al, 1989) and 
can specifica lly upregulate CD23 gene expression (Wang, et al, 1987). 
CD23 induction may therefore  be an im portant pathway fo r EBNA-2
induction and EBV infection.
CD23 is synthesised as a 45 kDa precursor and is expressed on the 
surface of B cells early after activation (Thorley-Lawson, et al, 1985), 
before being shed into the culture medium in a 25 to 33 kDa soluble form 
(sCD23). Several functions have been described for sCD23 including the 
control of IgE synthesis and cytok ine-like  properties such as fever 
induction , m ig ra tion  in h ib itin g  fa c to r a c tiv ity , B ce ll grow th and
d ifferentia tion and an accessory role in T cell p ro life ra tion  (Gordon,
1991). H igher levels of sCD23 have also been seen in H IV-infected
patients as compared to healthy individuals (Hober, et al, 1993).
CD23 has been shown to be the low affin ity  receptor for the Fc 
fragment of immunoglobulin E. CD23 (FceRII) is found on the surface of a
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varie ty  of haem atopo ie tic  ce lls  inc lud ing  lym phocytes, m onocytes, 
eosinophils, and platelets (Gonzales-Molina, et al, 1977, Delespesse, et al,
1986, Spiegelberg, et al, 1980, Capron, et al, 1981, Joseph, et al, 1986). 
The molecule was firs t d iscovered when Spiegelberg and co lleagues 
showed low a ffin ity  binding of IgE to human B lym phocytes. W ith an 
association constant of 1 0 7 M '1, the receptor responsib le was c learly  
distinct from the high affin ity IgE receptor of mast cells and basophils. 
The 45 kDa receptor is a glycoprotein without a signal sequence (Suter, e t 
al, 1987). The extracellu lar portion of FceRII is cleaved p ro teo ly tica lly  
(N a k a jim a , et al, 1987) and fragm ents are released which retain their 
ability to bind IgE.
CD23 - expressed only weakly on a m inority of freshly isolated, 
resting B cells from peripheral blood or tonsil - is both dram atically and 
rapidly upregulated on the B cell surface follow ing activation by stim uli 
such as EBV, phorbol esters and interleukin 4 (IL-4). IL-4 can induce the 
expression of low affin ity receptors for IgE (CD23) and class I I  MHC 
antigen on resting B lymphocytes (Defrance, et al, 1987, Rousset, et al, 
1988). S tim u la tion  of B ce lls  w ith in so lub ilised  an ti-IgM  an tibody 
increases the number of cells expressing CD23 upon culturing with IL-4 
and enhances the level of CD23 expression on these cells. CD23 induction 
is specific for IL-4 since IL-1a, IL-2, IFN-y, B cell-derived B cell growth 
factor (BCGF), and a low molecular weight BCGF were ineffective. None of 
these lym phokines acted syn e rg is tica lly  w ith  IL-4. IFN-y s trong ly  
inhibited the induction of CD23 and class I I  MHC antigen (Defrance, et al,
1987, Rousset, et al, 1988). Both cons titu tive  and induced CD23 
expression is a feature restricted to primary B cells bearing IgM/lgD. All 
EBV-immortalised B cell lines are CD23-positive.
On appropriate activation into cycle or fo llow ing transform ation by 
EBV, B cells release soluble cleavage products of the 45 kDa membrane 
molecule that contain autocrine grow th-prom oting activ ity. In addition, 
C D 23" cells, norm ally poor responders to polyclonal activators, become 
responsive in the presence of soluble CD23 preparations particularly when 
co-cultured with fixed or irradiated CD23+ cells. The grow th-prom oting  
actions of IL-4 also relate closely to the release of soluble CD23 in 
activated B cell cu ltures. A n tigen-specific  B-cell b lasts generated by 
im m unisation w ith te tanus toxoid were found to e lic it enhanced IgE
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antibody production in vitro in the presence of medium conditioned by 
EBV-transformed lym phoblastoid cells. The activ ity responsible could be 
removed and neutra lised spec ifica lly  by CD23 antibod ies. This data 
suggests that CD23 is involved in general B cell regulatory pathways.
Sarfati and co lleagues were the firs t to isolate an IgE-binding 
factor equ iva len t to so lub le  CD23 from the superna tan ts  of EBV- 
im mortalised B cell lines and they showed that it could modulate IgE 
production in primary B cell cultures. An antibody to CD23 was found to 
ablate IL-4 promoted IgE synthesis from peripheral blood m ononuclear 
cells. IgE reacts with and influences the behaviour of membrane-bound 
CD23, upregulating the receptor due to stab ilisa tion  by prevention of 
cleavage (Suter, et al, 1989).
Two species of FceRII (Fc£R lla/F ce R llk ) have been identified. They
differ by six am ino acids at the cytop lasm ic N -term inus. FceRMa is  
expressed in normal B cells and in certain B cell lines, whereas FceR II^  is
detectable in several leukocytic cell types such as T cells, eosinophils and 
monocytes. A lthough FceRII^ is not found on normal B lymphocytes and
monocytes, it can be induced by IL-4. IL-4 causes a two- to four-fold 
upregulation of the FceRI!a promoter activity (Suter, et al, 1989). The DNA
element responsive to IL-4 maps to the first 250 bp of the 5 ’ flanking 
region.
Infection of B cells with EBV in vitro  results in the ir polyclonal 
activation and im m orta lisation into lym phoblasto id cell lines. A lthough 
all mature B lymphocytes will bind and internalise virus particles, only a 
small percentage of cells actually become activated and/or im mortalised 
after infection (Tosato, 1987). The CD23 antigen has been used to separate 
immortalised and non-im m ortalised cells after EBV infection (Azim, et al, 
1988). The vast m ajority of cells expressing cytoplasm ic immunoglobulin 
are negative for CD23 and for EBNA, and are non-immortalised. Conversely, 
the CD23 positive, im mortalised population are positive for EBNA and 
negative for cytoplasm ic immunoglobulin. This indicates a d iversity in the 
response of B lym phocytes to EBV infection and suggests separate 
pathways for term inal d ifferentia tion and im m orta lisation.
CR2(CD21) and CD23 (FceRII) are normal B cell molecules expressed
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early during B cell activation and are implicated in the regulation of cell 
cycle. They are also regularly expressed on LCL cells. This supports the 
suggestion tha t EBV m ight activate the norm al B cell p ro life ra tion  
pathway and contribute to the establishm ent of an autocrine secretion 
loop of B cell growth factors during B cell immortalisation. A set of B cell 
activation molecules, including the EBV receptor CR2 (CD21) and the B cell 
activation antigen CD23, is turned on by in fecting  EBV-negative B 
lymphoma cell lines with immortalising strains of the virus B95-8. The 
P3HR1 non-im m orta lising strain of the virus, which is deleted for the 
entire EBNA-2 protein open reading frame, is incapable of inducing the 
expression of CR2 and CD23, suggesting a crucial role for EBNA-2 in 
activating these molecules (Cordier, et al, 1990).
B lymphocytes require co-operation with other cell lineages in order 
to initiate, augment, or maintain their activation to clonal expansion and 
exp ress ion  of th e ir  e ffe c to r fu n c tio n . C om p lem en t com ponen ts , 
in terleukin-1  (I L -1 ) and T ce ll derived  fa c to rs  rep resen t so lub le  
mediators which contribu te  to these processes (Gordon, et al, 1986). 
CD23, one of the firs t lineage-restric ted antigens to appear on the 
activation of human B ce lls, conveys grow th in fo rm ation  which is 
identical to that elicited by a T cell derived, low m olecular weight BCGF 
(B cell growth factor).
CD23 is involved in triggering  the progression of activa ted B 
lymphocytes through the G1 phase of the cell cycle (Gordon, et al, 1986). 
It has been suggested that CD23 m ight have a dual role in B cell 
proliferation : the surface molecule m ight act as a growth factor receptor, 
and the processed molecule itself acts as a growth factor. Activation of 
CD23 expression could be implicated in the establishment of an autocrine 
loop of growth factors. EBV-transformed B cells expressing FceRII release 
IgE-BFs into cu ltu re  superna tan ts, which enhanced IgE synthesis, 
suppressed IgG synthesis but had no significant effect on IgA and IgM 
synthesis (Sarfati, et al, 1984).
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The human CD23 gene promoter region:
Bam HI a  ^  Bam HI Bam HI Bam HI Bam HI
ii
■  I
III IV
The 4.5 kb genomic fragment encoding the 5’ portion of the CD23 
|gene is shown with the type a and typeJb promoters ( ),the
unique type a first and second exons ( |J  ), the unique type b first 
exon ( □  ), and the third and fourth exons which are common to 
both mRNA types ( |  ). Bam HI sites are indicated.
(Suter, et al, 1987, Yokota, et al, 1988).
O rganisation of the human CD23 gene prom oter region is 
complex. Transcription occurs from 2 independent prom oters giving rise, 
through alternative splicing, to three RNA species which are translated in 
proteins called CD23 type a and type b, diverging in their intracytoplasmic 
domains (C ord ier-B ussat, et al, 1993). Epstein-Barr virus nuclear antigen 
2 (EBNA-2) is an essential gene for EBV induced B lym phocyte growth 
tra n s fo rm a tio n  (C o h e n , et al, 1991). S ing le  gene tra n s fo rm a tion  
experim ents dem onstra ted that EBNA-2 spec ifica lly  upregu la tes EBV 
latent membrane protein 1 (LMP-1), and cellu lar CD21, CD23 and c - fg r  
gene expression (Abbot, et al, 1990, Knutson, 1990, Wang, et al, 1987). 
EBNA-2 gene transactivation is an essential occurrence for EBV-induced 
growth transformation and immortalisation (Cohen, et al, 1991).
All EBV-transformed lymphocytes express high CD23 levels, and 
EBV immortalised B cells arise from the subpopulation of cells expressing 
CD23 soon after infection. Even though CD23 expression in B lymphocytes 
is norm ally downregulated after im m unoglobulin  isotype sw itch, EBV- 
transform ed B cells which have sw itched to im m unoglobulin  G or A 
expression continue to express high CD23 levels (Kikutani, et al, 1986). 
B lymphoma cell infection with non-transform ing EBV (P3HR-1) induces 
little CD23, whereas transforming EBV infection induces high CD23 levels 
(Calendar, et al, 1987). Recombination of EBNA-2 into the P3HR-1 genome 
results in the restoration of transform ing ab ility  and CD23 induction.
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Differences in the growth phenotype of type 1 and type 2 EBV-transformed 
B lymphocytes correlate with differences in CD23 expression levels. As 
well as transform ing B cells less efficiently, type 2 EBVs also induce less 
CD23 than type 1 after in vitro  in fection  of EBV negative  B u rk itt’s 
Lymphoma cells (Calendar, et al, 1987). These EBV type-specific effects 
are due specifically to EBNA-2 (Cohen, et al, 1989). An important role for 
CD23 in EBV induced growth transfo rm ation  is suggested by the 
observation that EBNA-2 and LMP-1 act synerg istica lly to induce CD23 
(W ang, et al, 1990). EBV in fection of B cells also in te rfe res with 
corticosteroid-m ediated regulation of CD23 (Paterson, et al, 1994).
Latent EBV infection and growth transformation of B lymphocytes is 
characterised by EBV nuclear and membrane protein expression (EBNA and 
LMP respectively). LMP1 preferentia lly increases FceRllb CD23 mRNA, 
while EBNA-2 expression increases FceR lla CD23 mRNA. However, 
co-expression of EBNA-2 and LMP-1 increase total CD23 mRNA without 
increasing the high relative abundance of FceRllb to FceRlla CD23 mRNA 
induced by LMP-1. Thus, LMP-1 likely activates the FceRllb CD23 promoter, 
while EBNA-2 more likely transactivates a regulatory element common to 
both the FceRlla and FceRllb promoters (Wang, et al, 1990).
EBNA-2 transactivates transcription of the CD23 promoter through a 
specific c /s -ac ting  DNA e lem ent (W ang, et al, 1991b). The m inimal 
c/'s-acting CD23 DNA element delineated so far is a 186 bp -275/-89 
type a CD23 promoter DNA fragment. This is contained within a type a 
promoter fragm ent (-335/+80) which is clearly EBNA-2 responsive (Wang, 
et al, 1991b). EBNA-2 type specific d ifferences in growth transform ation 
correlate with the ir effects on CD23 expression rather than the ir effects 
on LMP-1 gene expression (Wang, et al, 1991b). EBNA-2 transactivation of 
the LMP-1 and the BAM Hl-C (BCR-2) promoters by type 1 versus type 2 
EBV has also been seen by infection with type 1 and type 2 EBV (Calendar, 
et al, 1987), infection with recombinant EBV containing type 1 or type 2 
EBNA genes (Cohen, et al, 1991), and stable transfection with type 1 and 
type 2 EBNA-2 in EBV-negative B-lymphoma cells (Wang, et al, 1990). In 
contrast, equal or stronger type 2 EBNA-2 transactivation of LMP-1 has 
been demonstrated by sim ilar LMP-1 levels in B cells transform ed with 
recombinant EBVs containing type 1 or type 2 EBNA-2 genes (Cohen, et al,
1991), by transfection of type 1 or type 2 EBNA-2 into B lymphoma cells
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infected with EBNA-2-deleted EBV e.g. P3HR-1 (Wang, et al, 1990), and by 
EBNA-2 co -tra n s fe c tio n  w ith LMP-1 genom ic DNA. The EBNA-2 
type-specific response of the CD23 c/'s-acting e lem ent is qua lita tive ly  
different to that of an LMP-1 c/'s-acting element to type 1 and type 2 
EBNA-2. This suggests that EBNA-2 transactivation of cell genes rather 
than viral genes is the basis for more efficient transform ing properties of 
type 1 EBV (Wang, et al, 1991b).
The jo in t interaction of EBV LMP-1 and EBNA-2 in inducing CD23 
d istingu ishes CD23 from  o ther B cell genes whose expression  is 
upregulated by a single EBV protein (Wang, et al, 1991a), and indicates 
that CD23 induction may be central to EBV-induced B lymphocyte growth 
transformation. EBNA-2 transactivates CD23 transcription through a DNA 
element which is EBNA-2 responsive. In addition, EBNA-2 transactivates 
LMP-1 (Wang, et al, 1991a) which activates the type b CD23 promoter 
(Wang, et al, 1990). In LM P-1-expressing cells EBNA-2 synergises with 
LMP-1 to induce high level type a and type b CD23 expression (Wang, et al,
1990).
The CD23 c/'s-acting DNA element is sim ilar in effects and location 
to an IL-4-responsive element mapped to the CD23 type a promoter region 
(-2 5 3 M 3 ) (Suter, et al, 1989), suggesting that EBNA-2 m ight usurp 
normal growth regulatory pathways. IL-4 induces low level type b CD23 
mRNA expression from normally undetectable levels in B lymphoma cells 
but also has a threefold effect on the type a CD23 mRNA (Yokota, et al, 
1988). Thus IL-4 appears to have effects on CD23 expression sim ilar to 
EBNA-2 rather than LMP-1, which preferentia lly  induces type b CD23 
mRNA (W ang, et al, 1990, Peng, et al, 1993). C ons titu tive  EBNA-2 
transactivation of an IL-4 responsive element may represent one signal 
contributing to EBV induced B cell immortalisation (Wang, et al, 1991b).
EBNA-2 transactiva tion  of the CD23 prom oter is dependent on 
interaction with a cellular DNA-binding protein, CBF-1 (Cp binding factor- 
1), which is essential for prom oter targeting (Sauder, et al, 1994). This 
interaction was first seen in EBNA-2 transactivation of the viral BCR-2 
(Cp) promoter (Ling, et al, 1994). A protein thought to be CBF-1 binds to a 
191 bp mapped EBNA-2 responsive region located at position -85 to 
-277 bp upstream of the CD23 promoter. The identity of this protein was 
confirmed by showing that the bound complex was competed for by the
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CBF-1 b inding site from  BCR-2, tha t the bound prote in  could be 
supershifted with a bacterially expressed fusion protein containing amino 
acids 252 to 425 of EBNA-2 but was unable to interact with a non-CBF-1- 
binding EBNA-2 mutant, and that in UV crosslink ing experim ents the 
BCR-2 CBF-1 binding site and the CD23 probe bound proteins of the same 
size (Ling, et al, 1994). A central core sequence, GTGGGAA, common to all 
known EBNA-2 responsive elements, is crucial for CBF-1 binding. Mutation 
of this core sequence abolishes CBF-1 binding, and the mutated sequence 
is unable to m edia te  EBNA-2 tra n sa c tiva tio n  (L ing , et al, 1993, 
Y a lam anch ili, et al, 1994). Flanking sequences on either side of this core 
influence the a ffin ity  for CBF-1. These d ifferences in a ffin ity  can be 
directly correlated with changes in the flanking sequences (Ling, et al,
1994). A s im ilar core sequence has been identified as a high affin ity 
binding site for the human recombination signal sequence binding protein 
RBP-Jk. CBF-1 has been purified and found to be identical to RBP-Jk. This 
protein binds to specific sequences in EBNA-2-responsive elements and 
recruits EBNA-2 to its cognate DNA sequences in vitro suggesting RBP-Jk 
may mediate EBNA-2 transactiva tion of both ce llu la r and viral genes 
(W altzer, et al, 1994, Z im ber-Strobl, et al, 1994).
A search of primate databases for the core sequence has identified 
more than 100 matches. It thus seems likely that CBF-1 may be involved 
in the regulation of the expression of a relatively large number of cellular 
genes, including other B cell activation antigens. The expression of these 
same genes could therefore be subject to modulation by EBNA-2, implying 
that EBNA-2 may have a much greater impact on B cell gene expression 
than was appreciated from the two known examples of EBNA-2 responsive 
cellular genes, c-fgr and CD23. Recent evidence has shown that other 
cellular factors are involved in m ediating EBNA-2 transactivation - the 
EBNA-2 mediated transactivation of LMP-1 is dependent on the binding of 
at least two distinct DNA-binding proteins (RBP-Jk and PU.1) (Johanssen, 
et al, 1995).
The regulation of CD23 gene expression is likely to be an important 
factor in EBV-induced B cell growth transformation. The purpose of this 
study was to explore the regulation of CD23 gene expression by EBV latent 
proteins. One approach in the definition of DNA sequences important in the 
regulation of gene expression is the placing of transcrip tiona l control
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elements (such as prom oter/enhancer sequences) from the CD23 gene 
upstream of a reporter gene. This facilitates measurement of the activity 
of the element. Ideally, such a reporter should encode a product which is 
stable, absent from the cell or organism in which it is being expressed, 
and be readily detectable in small quantities. In the course of this study, 
two reporter-based assays were investigated.
(a) Use of E. coli CAT (chloramphenicol acetyltransferase) as a 
reporter gene.
The E. coli CAT gene, which encodes the enzyme chloramphenicol
acetyl transferase has been used as a reporter gene in a variety of
cultured animal cell systems. This is a bacterial drug resistance gene
which inactivates chloramphenicol by acetylating the drug at one or both 
of it’s two hydroxyl groups. This gene is not found in eukaryotes and thus 
there is no background activ ity  in a normal m am m alian ce ll. This 
characteristic, along with the ease and sensitiv ity of assay, has made
CAT the most w idely used reporter gene in mammalian gene expression 
studies. There are a number of chromogenic and radioassays that allow 
rapid and sensitive detection of CAT, including a simple phase extraction 
assay. This involves incubating the cell extracts with 3H -ch lo ra m p h e n ico l 
and butyryl CoA. The butyrylated chloramphenicol is separated from the 
unmodified form by a simple phase extraction.
(b) Use of a human placental alkaline phosphatase gene in 
transfected cells as a reporter.
Human placental alkaline phosphatase (PAP) can also be used as a 
reporter gene in tran s fe c tio n  assays (H enthorn , e t al, 1988), its 
expression being dependent on the presence of exogenous transcription 
control elem ents. The enzymatic assay m easures the hydrolysis of p- 
nitrophenyl phosphate to p-nitrophenol (which is a yellow compound that 
can be measured spectrophotom etrically) plus inorganic phosphate. The 
assay is quan tita tive , rapid and inexpensive , using nonrad ioactive  
substrates and no specialised equipment. The enzyme’s resistance to heat 
allows it ’s ac tiv ity  to be easily d istinguished from  other endogenous 
alkaline phosphatase activities in mammalian cells. Activ ity can also be 
detected in ind iv idua l fixed ce lls by using a h istochem ica l stain for 
alkaline phosphatase. Sensitivity has been shown to be comparable to that 
achieved using CAT as the reporter enzyme (Henthorn, et al, 1988).
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2. Materials and Methods (Maniatis, etai, 1989).
2.1 Bacterial strains and plasmids:
E. coli D H 5a Genotype : F ', end  A1, hsdR17 (rk-,m k+), sup E44, th i -1, k-, 
rec A1, gyr A96, re! A1, <j>80/ac Z5M 15.
P lasm id D escrip tion  Source
pSV2APap Human placental alkaline Dr. Susan McDonnell,
phosphatase gene under the D.C.U.
control of the SV40 early
prom oter.
pBCD23 Hind II - Bam HI fragment of the Dr. Aude le Roux,
CD23 promoter cloned into l’ Institut Gustave
pBlueskript SK (Stratagene). Roussy, Paris.
pGem7ZF Commercial cloning vector 
from Promega.
Promega.
pGem3Zf Commercial cloning vector 
from Promega.
Promega.
pG7CAT CAT gene (Cla I - Bam HI) 
cloned into pGem7Zf
Dr. Aude le Roux.
pCMVCAT CAT gene under the control of Dr. Aude le Roux, 
the viral CMV promoter.
pCD23CAT CD23 promoter and CAT genes 
cloned into pBlueskript SK.
Dr. Aude le Roux.
pCMVEBNA2 EBNA2 gene under the control 
of the CMV promoter.
Dr. Aude le Roux.
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Plasm id D escrip tion  Source
pCMVEBNA3A EBNA3A gene under the control Dr. Aude le Roux.
of the CMV promoter.
pG7CD23 Bam Hl-Sal I CD23 fragment 
from pBCD23 cloned into 
pGem7Zf (digested with 
Bam HI and Sal I).
This study.
pG3CD23
pCD23Pap(a)
BamHI-Sal I CD23 fragment 
from pBCD23 cloned into 
pGem3Zf (digested with 
Bam HI and Sal I).
PAP gene isolated as an Eco Rl 
fragment from pSVaAPap cloned 
in the forward orientation into 
the Eco Rl site of pG7CD23.
This study.
This study.
pCD23Pap(b) PAP gene isolated as an Eco Rl 
fragment from pSV2APap cloned 
in the reverse orientation into 
the Eco Rl site of pG7CD23.
This study.
pG7CAT CAT gene cloned as a Hind III 
fragment into the Hind III site 
of pGem7Zf.
This study.
2.2 Bacterial media
All media was autoclaved at 15 lbs/in2 for 20 minutes. 
LB
1 0 g tryptone 
10g NaCI 
5g yeast extract
to 1L with distilled water (final pH 7.5)
for solid media 13g/L of oxoid agar no. 3 was added.
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SEB
LB +10 mM MgCl2 + 10 mM M gSO ^
SEB + 20 mM glucose. 
pH 6 .9-7.0.
2.3 Selective agents for bacterial culture
A n tib io t ic s
For the selective growth of transformed E. co li. am picillin was added to 
the media a fte r au toclav ing  and cooling to 65°C . S tock so lu tio ns
(25 mg/ml) were made in sterile water, stored at -20°C, and used at a
working concentration of 60^ig/m l.
X-aal (5 -B ro m o -4 -ch lo ro -3 -in d o lv l-p -D -a a la c to s id e ).
For the blue/white selection of recom binant plasm ids containing inserts 
that have disrupted the LacZ gene, x-gal, a chrom ogenic substrate for 
p-galactosidase was incorporated into the media after autoclaving and 
cooling. S tock so lu tions (20 m g/m l) were made in DMF (d im ethyl 
formamide) and stored at -20°C. A working concentration of 2 0 fxg/ml was 
used.
2.4 Bacterial growth and storage.
DH5oc was grown at 37°C and stored short term on LB plates, or long term 
as a glycerol stock. Glycerol stocks were prepared as follows :
To 1 ml of an overnight 5 ml culture of bacteria containing the appropriate 
selective agent, 1 ml of 50% glycerol was added. A fter vortexing, the 
stocks were transferred to -80°C .
2.5 Preparation of competent cells.
This method is a modification of the method of Hanahan (J. Mol. Biol. 1983 
vol 166, p557-580).
(1) From an overnight 5ml culture of DH5a, 1 ml was seeded into 100 ml of 
SEB medium.
(2) The culture was grown with shaking at 37°C  until the O.D. at 550 nm 
reached 0.45-0.6.
(3) The culture was then spun for 12 min, 2,500 rpm at 4 °C .
(4) The pellet was resuspended in 33 ml of FSB (Frozen Storage Buffer)
Frozen storage buffer
10 mM potassium acetate pH 7
100mM potassium chloride
45mM MnCl2-4H20
10 mM CaCl2-H20
1 0 % glycerol
0.1 M HCI added to final pH 6.4
(5) The cells were then incubated on ice for 10 min, spun at 2,500 rpm for 
10 min at 4°C, and resuspended in 8 ml FSB (4°C ).
(6 ) DMSO (280 |il) was added, and the cells were incubated on ice for 10 
min.
(7) Aliquots were prepared in prechilled tubes (200 ^il), flash frozen in 
liquid N2 and stored at -80°C .
2.6 Transformation of competent cells.
(1) Cells (from 2.5) were thawed on ice.
(2) DNA was added and mixed gently.
(3) After incubation on ice for 30 min, the cells were heat shocked for 90 
secs at 42 °C .
(4) SEB was added (1 ml), mixed, and incubated at 37°C  for 1 hour with 
a g ita tio n .
(5) The cells were then pelleted (4,000 rpm, 5 min), resuspended in 
200 (jl SEB and plated out on media containing the appropriate antibiotic 
(+/- x-gal).
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2.7 Small scale preparations of plasmid DNA (miniprep)
H arvesting
(1) A single bacteria l colony was transferred into 5ml of LB medium 
containing the appropriate antibiotic in a loosely capped 20  ml tube and 
incubated overnight at 37°C  with vigorous shaking.
(2) The culture was poured into a microfuge tube (1.5 ml) and spun at 
10,000rpm for 5 min.
(3) As much of the medium as possible was removed by aspiration.
Lysis
This is a modification of the methods of Birnboim and Doly (1979) and 
Ish-Horowicz and Burke (1981).
(1) The bacterial pellet was resuspended in 100|il of ice cold Solution I by 
vigorous vortexing.
Solution 1 
50 mM glucose 
25mM Tris.CI pH 8 
10 mM EDTA pH 8
(2) After resuspension was complete, 200 \i\ of freshly prepared solution 
2 was added and mixed thoroughly by inversion.
Solution 2
0.2 N NaOH (freshly diluted from a 10 N stock)
1 % SDS
(3) After mixing, 150 \i\ of ice cold solution 3 was then added and mixed.
Solution 3
5m potassium acetate 60 ml 
glacial acetic acid 11.5 ml 
H 2 O 28.5 ml
(4) The lysate was centrifuged at 10,000 rpm for 5 min and the 
superna tan t was trans fe rred  to a fresh tube, avo id ing  the white 
p re c ip ita te .
(5) An equal volume of phenol:chloroform :isoam ylalcohol (25:24:1) was 
added. The mixture was vortexed and centrifuged for 4 min at 10,000 rpm 
and the upper phase was transferred to a fresh tube.
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(6 ) The DNA was precipitated by adding 2 volumes of ethanol, vortexing, 
incubating for 5 min at room temperature, and centrifuging for 10 min at
1 0 ,0 0 0  rpm.
(7) The supernatant was removed by aspiration. The pelle t was then 
washed with 500jxl of 70% ethanol, dried, and resuspended in 50 p,l of TE 
(pH 8 ) containing DNAse-free RNAse (20 mg/ml).
2.8 Large scale preparations of plasmid DNA (maxiprep).
Lysis by alkali.
(1) The bacterial pellet from a 500 ml culture was resuspended in 18 ml 
of Solution 1.
(2) A freshly prepared solution of lysosyme (10 mg/ml in 10 mM Tris.Cl pH 
8 ) was added (2 ml).
(3) Then, 40 ml of freshly prepared Solution 2 was added, the solution 
mixed by inversion.
(4) A fter incubation at room temp for 5-10 min, 20 ml of ice cold 
solution 3 was added, mixed by inversion and stored on ice for 10 min.
(5) The lysate was centrifuged at 4,000 rpm for 20 min at 4 °C  in a Sorvall 
GS3 rotor.
(6 ) The supernatant was filtered through Whatman no. 1 filter paper into a 
250 ml centrifuge bottle, 0.6 volume of isopropanol was added, mixed well 
and stored at room temp for 10  min.
(7) DNA was precipitated by centrifugation for 20 min at 5,000 rpm.
(8 ) The supernatant was removed, the pellet washed with 70 % ethanol, 
and allowed to dry.
(9) The pellet was resuspended in TE pH 8 .
Purification by CsCI gradients.
(1) For every ml of DNA solution 1g of solid CsCI was added, the solution 
warmed to 30°C to facilitate dissolution, and mixed gently.
(2) Ethidium bromide solution (10 mg/ml in water) was added (0.8 ml for 
every 10 ml of DNA/Cs solution) and immediately mixed. (The final density 
should be 1.57 g/ml).
(3) The solution was transferred to a Beckmann quickseal tube, the 
remainder of the tube filled with mineral oil and sealed.
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(4) Centrifugation was done in a Ti70.1 rotor at 50,000 rpm for 24 hr at 
20 °C . Two bands should be visible. The upper band contains chromosomal 
and nicked plasmid DNA, the lower band contains the closed circular 
plasmid DNA.
(5) To collect the bands :
A 20-gauge needle was inserted into the top of the tube to allow air to 
enter. An 18-gauge needle was then inserted below the band of interest 
and the DNA was collected in a 2 ml sterile syringe.
(6 ) The ethidium bromide was removed from the DNA solution by repeated 
extractions with TE-saturated isobutanol.
(7) The DNA was dialysed against TE for 24 hr with several changes of 
buffer to remove the CsCI.
Purification by column isolation.
The plasmid DNA was a lternate ly isolated using the Promega Wizard 
Maxiprep Column System.
2.9 Solutions for DNA work
0.5 M ED TA: 186.1 g added to 800 ml water. Add 6 g NaOH
50XTAE :
Agarose gel loading dye :
5XTBE :
Ethidium bromide :
DNAse-free RNAse :
pellets. pH to 8.0 w ith 5M NaOH. Adjust 
volume to 1L with water.
242g Tris
57.1 ml acetic acid.
100 ml 0.5 m EDTA pH 8.0 
to 1 L with water.
54 g Tris
27.5 g Boric acid
20 ml 0.5 M EDTA pH 8.0
to 1 L with water.
0.1 g/ 10 ml water (10 mg/ml). Protect from 
lig h t.
RNAse A (1 mg/ml) in sterile water.
100°C  30 min.
Cool slowly, store -20°C .
40% sucrose
0.25% bromophenol blue.
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2.10 Storage of DNA samples
DNA samples should ideally be stored in TE buffer pH 8.0 at 4°C . The use of 
EDTA chelates heavy metal ions that are com monly needed for DNase 
activity while storage at pH 8 minimises deamidation 
TE buffer
10 mM Tris, 1mM EDTA pH 8.0
2.11 Equilibration of phenol
Before use, phenol was equilibrated to pH 8.0 as DNA partitions into the 
organic phase <pH 7.8
(1) Solid phenol was melted at 6 8 °C , and hydroxyquinoline was added to a 
final concentration of 0 .1% (acts as an antioxidant, a chelator of metal 
ions, and an RNase inhibitor).
(2) An equal volume of buffer (0.5 M Tris.C l pH 8 ) was added to the 
liquefied phenol and stirred for 15 minutes. The two phases were then 
allowed to equilibrate and as much as possible of the upper aqueous phase 
was removed.
(3) The extraction was repeated using equal volumes of 0.1 M Tris.Cl pH 8 
until the pH of the phenol was > 7.8.
(4) Tris.Cl pH 8 (0.1 volume) and 0.2% p-m ercaptoethanol were added to 
the phenol, which was the stored at -20°C  in the dark.
2.12 Ethanol precipitation of DNA
Concentration of nucleic acid samples or changing the buffers in which a 
sample is dissolved was achieved by ethanol precipitation.
(1) In general one tenth volume of 3 M sodium acetate pH 5.5 and 
2 volumes of ethanol were added to a DNA sample.
(2) The sample was mixed by inversion and incubated at either -80°C  for 
30 min or -2 0 °C  overnight.
(3) The sample was then centrifuged at 10,000 rpm for 30 min, washed 
with 70% ethanol to remove excess salts, dried, and resuspended in 
suitable buffer.
Notes on precipitation :
(a) To prevent the co-precip ita tion of dNTPs 0.5 volum es of 7.5 M
ammonium acetate can be substituted for sodium acetate.
(b) To remove SDS from a sample, the sample can be made 0.2  M in sodium
chloride before the addition of ethanol.
(c) If the DNA to be precipitated is small i.e. <200bp, the sample should 
also be made 10mM in magnesium chloride before ethanol precipitation.
2.13 Spectrophotom etric quantification of DNA
In general, for quantification of maxiprep DNA, 5^il of DNA was added to 
4 9 5 |il of distilled water. Absorbance readings were taken at 260 nm and 
280 nm. An absorbance reading at 260 nm of 1 corresponds to approx. 
50ng/m l of double stranded DNA. The ratio between the readings at 260 
and 280 nm provides a measure of the purity  of the DNA. A pure
preparation of DNA will have a 260/280 ratio of between 1.8 and 2.0.
2.14 Agarose Gel Electrophoresis of DNA
Electrophoresis through agarose gels is the standard method used to 
separate, identify and purify DNA fragm ents. The technique is simple,
rapid to perform, and can be used for the isolation of DNA fragments.
Agarose gels were prepared and run as follows :
(1) An appropriate quantity of agarose was boiled in 0.5X TBE buffer until
dissolved and allowed to cool to 60°C before pouring.
(2) DNA samples were mixed with loading buffer and run at a constant
voltage of 5V/cm (measured as the distance between the electrodes) for 
1-2  hours.
(3) A fter e lectrophoresis, the gel was stained in a bath of ethidium  
brom ide so lu tion (0.5fxg/m l) for 20 m inutes, fo llowed by desta in ing in 
water for 15 minutes. The gel was then viewed under UV illumination.
2.15 Isolation of DNA from aaarose gels.
A number of methods were used to isolate DNA from agarose gels :
(A) Low melting point agarose
(1) A low melting point agarose was prepared in 1X TAE buffer (gel 
isolation is not carried out in TBE buffer as borate ions are d ifficu lt to 
remove from the resultant DNA solution).
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(2) After electrophoresis, the gel was stained in an ethidium bromide bath 
and viewed under 70% UV illumination. The time of exposure to UV light 
was kept to a minimum, as overexposure to UV causes damage to the DNA.
(3) The DNA band to be isolated was excised from the gel using a scalpel 
and placed in a sterile microfuge tube. About 5 volumes of 20 mM Tris.CI, 
1 mM EDTA (pH 8 ) was added to the gel slice and incubated at 65°C for 5- 
10 minutes to melt the gel.
(4) After cooling to room temperature, an equal volume of phenol (pH 8 ) 
was added, the sample vortexed and centrifuged for 10 min at 4000 rpm.
(5) The aqueous phase was re-extracted once with phenol:chloroform  and 
once with chloroform.
(6 ) 10 M ammonium acetate (0.2 volumes) and 2 volumes of ethanol at 4°C 
were added to the sample. After incubation at -20°C overnight, the DNA 
was recovered by centrifugation at 1 0 ,0 0 0  rpm for 20  minutes.
(B) E lec troe lu tion
(1) An agarose gel was prepared in TAE buffer. For DNA isolation a high 
grade agarose was used (Seakem GTG agarose). This is to minimise the 
chance of introduction of contam inants such as DNAses into the DNA 
sample.
(2) The gel slice containing the DNA band of interest was placed into a 
dialysis bag containing a small amount of running buffer. This was then 
immersed in a shallow layer of 1X TAE in an electrophoresis tank and 
subjected to an electric current of 4-5 V/cm for 2 hours. During this time 
the DNA is eluted on to the surface of the dialysis bag.
(3) The current was reversed for 1 minute to release the DNA from the 
wall of the bag, and the buffer was removed from the bag.
(4) The DNA was purified by phenokchloroform  extraction and ethanol 
precipitation. (The process was checked by staining the gel slice to ensure 
all the DNA had been eluted).
(C) Spin columns
(1) The DNA was isolated from a seakem agarose gel as before and 
transferred to a spin column. These columns are com m ercially available 
(from Costar) and contain a 0.2^im cellulose acetate membrane.
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(2) The agarose slice is first frozen at -80°C for 30 min, then centrifuged 
for 20  min at 1 0 ,0 0 0  rpm.
(3) The resulting solution is then cleaned by phenokchloroform  extraction, 
and the DNA isolated by ethanol precipitation.
2.16 Preparation of dialysis tubing.
Dialysis tubing was boiled for 10 min in 1 mM EDTA, rinsed thoroughly 
with distilled water, and stored at 4°C.
2.17 Decontamination of ethidium bromide solutions.
This method was developed by Lunn and Sansone (1987).
(1) S u ffic ie n t w ater was added to reduce the co n cen tra tion  of 
ethidium bromide to <0.5 mg/ml.
(2) 0.2 volume of fresh 5% hypophosphorus acid and 0.12 volume of 
fresh 0.5M sodium  nitrate was then added. The solu tion was mixed 
carefully and the pH was checked (should be <3).
(3) A fter incubation for 24 hr, a large excess of sodium bicarbonate 
was added and the solution was discarded.
2.18 Restriction digestion of DNA
Restriction enzymes bind specifically to and cleave double stranded DNA 
at specific sites within or adjacent to a particular sequence known as the 
recognition site.
The restriction enzymes used were supplied with incubation buffers 
at a concentration of 10X (working concentration 1X). DNA digests were 
done by adding 1 unit of enzyme/^ig of DNA solution, and incubating for 2 
hours at the optimum enzyme temperature (usually between 30 and 37°C). 
The final DNA concentration in the digest should be between 100 and 
300 ng/^l for maximum digestion.
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2.19 Ligation of DNA molecules
Several strategies for ligation of DNA molecules are available depending 
on the nature of the termini.
(1) Cohesive termini.
Ligations of equimolar amounts of vector and insert DNA were carried out 
overnight at 16°C in a commercial ligation buffer (5mM ATP) with 10 
Weiss units of ligase/m l. A fter ligation, the sam ples were heat treated 
for 10 min at 70°C to inactivated the ligase (this appears to improve 
transfo rm ation  e ffic ienc ies ).
(2) Blunt term ini.
Compared to cohesive term ini ligations, the ligation of b lunt term ini is 
considerably less efficient. The reaction conditions used were the same, 
except for the use of low concentrations of ATP (0.5 mM), the addition of 
high concentra tions of ligase (50 W eiss un its /m l) and the use of 
condensing agents. These are substances that increase m acrom olecular 
crowding and hence increase the concentration of blunt ended term ini. 
Hexamine cobalt chloride was used at a concentration of 1|iM .
During liga tion , T4 DNA ligase will catalyse the form ation of a 
phosphodiester bond between adjacent nucleotides only if one contains a 
5 ’ phosphate group and the o ther conta ins a 3 ’ hydroxyl group. 
Recircularisation of plasmid DNA can therefore be minimised by removing 
the 5 ’ phosphate groups by treatm ent with calf in testinal phosphatase 
enzyme (CIP).
Dephosphorylation of linearised plasmid DNA.
(1) Vector DNA (5^ig) was d igested w ith the appropria te  restric tion  
enzyme in a volume of 2 0 |il.
(2) The sample volum e was brought to 150|al w ith w ater (includ ing 
dephosphorylation buffer to a concentra tion of 1X). CIP was added 
(1 unit/1 0 0  pmoles for cohesive term ini and 1 unit/2  pmole for blunt 
termini) and the sample incubated at 37°C for 1 hour.
(3) The DNA was then purified  by phenol extraction  and ethanol 
p re c ip ita tio n .
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2.20 In situ colony screening by hybridisation.
P rin c ip le
DNA is labelled by random primed incorporation of d igoxygenin-labelled 
deoxyuridine-triphosphate. The dUTP is linked via a spacer arm to the 
steroid hapten digoxygenin (DIG-dUTP). A fter hybridisation to the target 
DNA, the hybrids are detected im munologically using an anti-D IG-alkaline 
phosphatase antibody conjugate and colorimetric assay.
Preparation of colony lifts
(1) The transform ants to be analysed were transferred to duplicate LB 
plates containing the appropriate antib iotic using sterile cocktail sticks.
(2 ) Plates were incubated at 37 °C  overnight, then chilled for one hour at 
4°C.
(3) A nitrocellulose filte r was placed on the plate for one minute, then 
transferred colony side up to blotting paper for 5-10 min to allow the 
cells to bind.
(4) The filter was placed colony side up on blotting paper soaked with 
denaturation solution for 15 min.
Denaturation solution  
0.5 N NaOH
1.5 M NaCI 
0.1% SDS
(5) The filte r was then placed onto b lo tting  paper soaked with 
neutralisation solution for 5 min, followed by transfer to paper soaked 
with 2 x SSC for 15 min.
N eutra lisa tion  so lu tion  
1 M Tris.CI pH 7.5
1.5 M NaCI 
20xSSC
3 M NaCI
0.3 M sodium citrate 
pH 7.0, autoclaved.
(6 ) The DNA was fixed by baking for 2 hours at 80°C  and cellu lar debris 
was then removed by incubation in 3xSSC/0.1% SDS with shaking for 1-3 
hours at 6 8 °C .
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DNA probe labe lling  bv random prim ing w ith d iooxvoen in -labe lled  
nuc leo tides
(1) The DNA was purified by phenol:chloroform  extraction and ethanol 
p re c ip ita tio n .
(2) The DNA was denatured by boiling for 10 min followed by quick chilling 
on ice.
(3) The labelling reaction was carried out as outlined in the Boehringer 
Mannheim DIG kit protocol.
H yb rid isa tion
(1) The filters were prehybridised as outlined in the kit instructions for 2 
hours.
(2) Hybrid isation was carried out overn igh t in the presence of 50% 
formamide at 42°C .
(3) 50 ng of probe was used.
Detection
(1) Detection was carried out as outlined in the kit instructions and the 
filters were air dried for storage.
Principle of DIG DNA labelling and detection system
Linear denatured DNA
+ random + dATP, dCTP, + DIG-dUTP + Klenow enzyme
hexanucleotides dGTP, dTTP
f \ j  r j  ru T
Synthesis of labelled DNA
r u  r j ---------- ;------- :-------► < \ J < \ J -T T  T
Dénaturation of 
probe
Hybridisation to 
filter bound DNA
r^j ru
+ anti-DIG-AP
T T
Antibody-hapten
complex
f\J  f\J
+ colorimetric 
substrate
Colour reaction
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2.21 Am plification of the CD23 5 ’ prom oter region by the
polymerase chain reaction (PCR)
DNA was amplified by PCR in 
follow ing :
10X PCR amplification buffer: 
dNTP mix 
primer A 
primer B
Magnesium chloride 
Template DNA 
Taq polymerase
a 100^1  reaction volum e contain ing the 
10nl
200p,M final conc of each dNTP
250 ng
250 ng
1.5 mM
10 ng
0.5 units
Sterile water added to final volume of 100fil.
Samples were overlaid with 60^ x1 of mineral oil and the amplification was 
carried out as follows :
Cycles D énatu ra tion A nnealing P o ly m e ris a tio n
1 940C, 2 min
30 94°C, 1.5 min 51 °C, 1 min 72°C, 1.5 min
1 72°C, 5 min
Primers used for CD23 amplification :
(1) Forward primer 1 : 5' gagaactctg tga ttcggccataat 3'
Sac I
52% GC, Tm=58°C, Ta=53°C.
(2) Forward primer 2 : 5' agaaactcacatc ttaacactacc  3'
Sac I
50% GC, Tm=54°C, Ta=49°C.
(3) Forward primer 3 : 5' aggagctctag ttc tcacccaat 3'
Sac I
45% GC,Tm=56°C, Ta=51°C.
(4) Reverse primer 4 : 5' gacccgggtgagaactaaaaatqt 3'
Sma I
47% GC, Tm=56°C, Ta=51°C.
(5) Reverse primer 5 : 5' ggc c c g g g ttta a g c a g g a a g a g a g  3'
Sma I
48% GO, Tm=56°C, Ta=51°C.
Annealing sequences are given in bold type.
Tm : melting temperature given by 2(A+T) + 4(g+C)
Ta : annealing temperature.
2.22 Generation of nested sets of deletion mutants by BAL 31 
nuclease d igestion­
s ' / .  31 Reaction Buffer (5X)
40 mM Tris.HCI pH 7.2 
25 mM MgCb 
25 mM CaCl2 
2 mM EDTA
1.2 M NaCI
A time course reaction for the generation of deletion mutants was carried 
out :
(1) The plasmid DNA was linearised, phenol extracted, precipitated, and 
resuspended in TE at a concentration of 1 jxg/|o.l
(2) The reaction mix was set up as follows :
60 |il of DNA
60 \i\ of BAL 31 reaction buffer 
2 |il of BAL 31 enzyme (1/10 dilution)
178 p.l of sterile distilled water
(3) Tubes were set up on ice containing 5 \i\ of 0.2 M EGTA.
(4) The reaction mixture was incubated at 30°C and 45 |il samples were 
removed to the tubes containing EGTA at selected time points (e.g. T = 0, 
10, 20, 30, 40, 50 min).
(5) The samples were heated to 65°C for 10 min to inactivate the BAL 31. 
To each sample, 5 |il of 3M sodium acetate pH 5.5 and 100 \i\ of ethanol 
were then added, mixed, the samples incubated for 30 min at - 80°C, and 
spun for 20  min at high speed.
(6 ) The pellets were dried and resuspended in 22 |il of TE buffer.
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2.23 Repair of DNA molecules to generate blunt ends
The DNA from BAL 31 digestion was repaired using a combination of T4 
DNA polymerase and Klenow. The reaction was set up as follows :
BAL 31 digested DNA 22^,1
dNTP mix (2mM each) 4|il
10X polymerase buffer 3(xl
T4 DNA polymerase (5 units) 1fxl 
The samples were incubated for 30 min at room temp, followed by the 
addition of 2 |il (4 units) of Klenow enzyme and incubation for 15 min. The 
samples were then phenol cleaned and precipitated.
2.24 Construction of a T vector for the cloning of PCR products.
Attempts to clone PCR products as blunt-ended fragm ents are generally 
very ineffic ient, due to the tem pla te-independent term ina l transferase 
activity of Taq polym erase, which results in the addition of a single 
nucleotide at the 3 ’ end of the fragm ent. This nucleotide is alm ost 
exclusively an adenosine, due to the strong preference of the polymerase 
for dATP (Hu, 1993) This characte ris tic  of Taq polym erase can be 
exploited for cloning if a T vector is used. The following reaction can be 
used to create a vector with a single thymidine addition at each 3 ’ end 
(Marchuk, et al, 1990).
Procedure :
(1) The plasmid (1.5 jug) was digested with a blunt-cutting enzyme in a 
volume of 20  il l for 2 hours.
(2) After digestion was complete, 6 (il of 3 M sodium acetate pH 5.5, 14 |xl 
of water and 120 |il of ethanol were added. After mixing, the sample was 
stored at -70°C  for 20 min, spun at 10,000 rpm for 20 min, dried and 
resuspended in 20  fil.
(3) The T reaction mix was prepared as follows :
10 (0,1 10X PCR buffer (including MgCl2)
10 fil 20 mM dTTP
20  ^1 plasmid
0.5 [xl Taq DNA polymerase
59.5 |il of water
(4) The reaction was overlaid with mineral oil and incubated at 70°C for 2 
hours.
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(5) The sam ple was then ex trac ted  w ith ph e n o l:ch lo ro fo rm  and 
precipitated with sodium acetate, resuspended at 50 ng/(il.
2.25 Cell lines.
(1) Suspension cultures :
DG75 - an EBV negative Burkitt’s lymphoma cell line (a gift from Dr. Aude 
le Roux, L’institut Gustave Roussy, Paris).
(Ref. : Ben-Basat, et al, (1977) Int. J. Cancer, 1_9, 27-33).
HuT 78 - ATCC TIB 160 (Human cutaneous T cell lymphoma)
(a gift from Stephen Ahern, Dept, of C linical M edicine, T rin ity  medical 
School, St. James’ Hospital, Dublin 8 ).
HuT 78 is a human T cell line which was derived from peripheral 
blood of a patient with Sezary syndrome. This line has properties of a 
mature T cell line with inducer/helper phenotype and releases T cell 
growth factor (IL-2). B iologically active IL-2 could also be eluted from 
the surface of these cells and subce llu la r frac tiona tion  showed that 
almost all the IL-2 activ ity was associated with the plasm a membrane. 
IL-2 activity is adsorbed by this line and HuT 102 (ATCC TIB 162) but not 
by other human tumour cell lines. Growth rate can be increased by the 
addition of IL-2. Ref : J. Exp. Med. 154 : 1403-1418, 1981.
(2) Adherent cultures :
SW480 ATCC CCL 228 (Colon, adenocarcinoma, human)
(a gift from Helen O’ Shea, Biology Dept. DCU).
The tumour of origin (Grade lll-IV  adenocarcinoma of the colon) was 
minced and various fractions of the resultant fragm ents were seeded to 
culture flasks in derivatives of L-15 medium supplemented with 10 % FCS, 
insulin (0.1 u/ml) and cortisol (10 u/ml). The population grew in itia lly as 
small islands of ep ithe lia l cells and individual b ipo lar cells becom ing 
predom inantly ep ithe lia l-like  once established. M icrovilli were apparent, 
carc inoem bryon ic antigen (CEA) was produced and the ce lls  were 
tumorigenic in nude mice.
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Hep G2 ATCC HB 8065 (Human hepatocellular carcinoma).
(a gift from Barbara Fingleton, Biology Dept, DCU).
This line was derived from tissue of a 15 year old male Caucasian. 
The cells are epithelial in morphology, have a modal chromosome number 
of 55 and are not tum origen ic  in nude m ice. The ce lls  produce 
a -fe top ro te in , a lbum in, a 2 -m a c ro g lo b u lin ,  a l-a n t it r y p s in ,  tra n s fe rrin , 
a 1 -a n t ic h y m o try p s in , h a p to g lo b in , c e ru lo p la s m in , p la s m in o g e n , 
com plem ent (C3, C4), C3 activator, fibrinogen, a 1 -a c id  g lyco p ro te in , 
a2-HS glycoprotein, p-lipoprotein and retinol binding protein. There is no 
indication that this cell line harbours an hepatitis B virus genome.
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Suspension cell cultures
DG75 (100X)
Adherent cell cultures (200X) 
S W 480
2.26 Growth media for cell culture
The culture of suspension cells DG75 and HuT 78 was carried out in 
supplemented RPMI media (10% foetal calf serum - FCS):
176 ml RPMI-1640 
20 ml FCS 
2 ml L-glutam ine 
2 ml Pen/strep
DG75 and HuT 78 cells were seeded at 5 X 105 cells/m l and split when 
they had reached a density of 1.5 x 106 ce lls/m l. This was done by 
counting the ce lls, cen trifug ing  them  at 800 rpm fo r 5 min, and 
resuspending them in fresh growth media.
The culture of adherent cell lines SW480 and Hep G2 was carried out in 
supplemented DMEM media (5% FCS) :
186 ml DMEM 
10 ml FCS 
2 ml L-glutamine 
2 ml pen/strep
SW480 and HepG2 cells were seeded at 1 x 106 ce lls /75cm 2 flask and 
sp lit when they had reached 75% confluency. This was done by 
tryps in isa tion , counting, cen trifuga tion  at 2000 rpm fo r 5 min and 
resuspension in fresh growth media.
2.27 Viable cell counting.
This is done by the addition of trypan blue to the cells - dead cells stain 
blue while viable cells remain clear.
(1) Cell suspension (90 \i\) was added to 10 \i\ of trypan blue dye and mixed 
w e ll.
(2) Cells were counted using a haemocytometer.
2.28 Preparation of cell stocks.
(1) Stocks were prepared in 1 ml aliquots using 107 cells per stock.
(2) Cells were harvested in exponential phase by centrifugation.
(3) The pellet was resuspended in 900 ¿il of supplem ented RPMI (20% 
serum) per 10 7 cells and incubated on ice for 10 min.
(4) DMSO was added (1 0 0  jliI per 1 0 7 cells) as a cryoprotective agent and
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the mixture was incubated on ice for 5 min.
(5) The mixture was transferred in 1 ml aliquots to cryotubes.
(6 ) Freezing was carried out at -20°C for 30 min, followed by -80°C for 12 
hours. The cells were then transferred to liquid nitrogen.
2.29 Reconstitution of frozen stocks
(1) Vials were thawed at 37°C.
(2) The cells were immediately transferred to 10 ml of growth medium to 
dilute the DMSO and centrifuged for 5 min at 800 rpm (suspension cells) or 
2000 rpm for 5 min (adherent cells).
(3) The pellet was then transferred to 10 ml of fresh growth medium in a 
culture flask.
2.30 Trypsinisation of adherent cells.
(1) The medium was removed from the cells and they were rinsed once in 
serum free medium and once in PBS (phosphate buffered saline). This
removes the serum from the cells which would inhib it the action of the
tryp s in .
(2) 2 ml of 0.25% trypsin/EDTA were added to the cells and they were 
incubated at 37 °C for 10 min.
0.25% trvpsin/EDTA
88  ml sterile PBS
2 ml sterile EDTA (1% w/v)
10 ml 2.5% commercial trypsin solution.
PBS (phosphate buffered saline
8 g NaCI
0 .2 g KCI
1.44g NaHP04
0.24g KH2P 0 4
800ml of d istilled water
pH was adjusted to 7.4 with HCI and the volume was made up to 1L.
(3) When the cells have detached, 5 ml of complete growth medium was 
added to stop the action of the trypsin. At this stage a sample can be 
taken for cell counting. The remainder was centrifuged at 2000 rpm for 5 
min.
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(4) Flasks were seeded at 1 x 106 cells/75cm 2 flask .
2.31 Transfection of adherent cell lines : CaPO/j technique.
Principle :
Plasmid DNA is mixed with calcium chloride and added to a solution 
containing phosphate ions. A calcium phosphate-DNA co-precip ita te  is 
formed which is taken up by mammalian cells in culture.
Solutions :
(1) 2x HBS (Hepes Buffered Saline) 280 mM NaCI 8 .18g
50 mM Hepes 5.96g 
1 .5m M N a2H P 04 0.13g 
500 ml ultra pure water 
Filter sterilise pH 7.12, store 4°C . 
The pH is critical for effic ient transfection (this can vary w idely between 
batches of 2x HBS) - the optimal pH is between 7.05 and 7.12. Efficiency 
can be checked by mixing 0.5 ml 2x HBS and 0.5 ml 2.5 M CaCl2 a n d  
vortexing. A fine precipitate should develop that is readily visible in the 
m icroscope.
(2 ) 2.5 M CaCI2
(3) Tris-EDTA (TE)
(4) 10% Glycerol/HBS 
Procedure :
Day prior to transfection :
(a) Cells were trypsinised, counted and set up at 5 x 105 cells into 10 cm 
tissue culture plates. On the day of transfection it is important that the 
cells are thoroughly separated on the dish as the ability to take up DNA is 
related to the surface area of the cell exposed to the medium.
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183.7 g CaCI2
500 ml ultra pure water
Filter sterilise, store 4 °C .
10 mM Tris 
1 mM EDTA 
pH 8.0
10 ml glycerol
50 ml 2x HBS
40 ml ultra pure water.
(b) Plasmid DNA was diluted to 1 (ig/ul in TE. Sterile water was added to 
the DNA (final volume 420 nl) and this was placed in a sterile 3 ml tube at 
4 °C overnight.
Dav of transfection:
(c) The tube containing the DNA was placed at 37 °C for 1 hour. At the
same time, 480 (xl 2 x HBS was placed into a 3 ml sterile tube at room
tem perature .
(d) The 2.5 M CaCI2 (60 nl) was added dropwise into the tube containing 
the DNA with continual m ixing using a vortex. The DNA-CaCl2 m ixture was 
immediately added into the 2x HBS. The DNA must be added dropwise into 
the HBS with continuous vortexing. This is the most important step - 
the finer the precipitate the better the transfection efficiency.
The samples were left in the laminar flow for exactly 30 min - this time 
is critica l so if there are a number of sam ples then they must be 
staggered so that each gets exactly 30 min.
(e) The cells were removed from the incubator and the DNA was added 
dropwise to the cells with gentle sw irling of the plate to ensure even 
mixing. The plates were then incubated at 37 °C for 4 hours.
(f) The cells were then glycerol shocked to aid the entry of the DNA into 
the cells :
1. The medium was removed.
2. Immediately, 3 ml of 10% glycerol/HBS was added.
3. The cells were left for 3 min e x a c tly  - overexposure to glycerol
w ill kill the cells.
4. The glycerol was removed, the cells were rinsed once in sterile 
PBS and once in serum free medium. They were then refed with 10ml 
of fresh growth medium.
2.32 Transfection of B lymphocytes by electroporation.
The following procedure works well for DG75 and T cells (gives about 90% 
k il l) .
(1) The cells were passaged 2 days before transfection. Cells should be 
less than 10®/ml(5-7 X 10^/m l).
(2) On the day of transfection 60 mm dishes were prepared with 5 ml 
RPMI-1640/glutamine/10% FCS (complete) and incubated at 37°C.
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(3) Cells were spun at 800 rpm for 5 min (1X107  cells /  transfection), and 
washed in one fifth volume of cold complete RPMI.
(4) During this cuvettes were prepared - labelled, on ice, and containing 
DNA.
DNA preparation
Transfected DNA was in 30 (J.I TE pH 7 .4 . There must be the same total 
quantity of DNA in each tube. The appropriate quantities of DNA were co­
precipitated, washed in 70% ethanol, dried and then resuspended in TE 
pH7.4.
(5) Cells were resuspended in cold complete RPMI at 250(il per 107  cells.
(6 ) C e lls/D N A mix was pulsed at 220V/960n,F (w ith  capac itance  
extender). The time was recorded in millisecs.
(7) Cells must not stay longer than 10 min in the cuvettes after pulsing.
(8 ) The contents of the cuvettes were g e n t ly  transferred to culture 
dishes using micropipette and yellow tip. The cuvettes were washed with 
medium from the dish.
(9) Transfected cells were incubated from 24 to 48 hours (37°C, 5% C 0 2).
(10) The cells were harvested for reporter enzyme assays (see 2.33)
2.33 Harvesting of cells post-transfection.
(a) Adherent cells
1. The medium was removed from the plates and the cells were washed 
twice with 5 ml of sterile TBS.
2. After washing, 1 ml of TBS was added and the cells were scraped off 
the plates and transferred to a sterile microfuge tube on ice.
3. Cells were spun at high speed for 1 minute.
4. The cell pellet was resuspended in 100 jxl ice cold TBS.
5. Cells were frozen for 5 min in dry ice/ethanol, followed by incubation 
for 5 min at 37 °C. This is repeated twice more. (Successive freezing and 
thawing lyses the cells).
6 . The lysate was cooled on ice and then spun for 5 min at 4 °C. The 
supernatant was removed and stored at -80 °C. (This is the cell extract 
that contains the transfected protein).
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(b) Suspension cells
1. Cells were pelleted at 1000 rpm for 5 min.
2 . The pellet was washed with 1 ml of TBS and transferred to a sterile
microfuge tube.
3. Preparation of the lysate was as per adherent cells.
2.34 PAP assay
PAP (placental a lkaline phosphatase) is resistant to heat and is also 
restricted in expression to the p lacenta. The assay m easures the
hydrolysis of PNPP (p-nitrophenyl phosphate) which gives rise to a yellow
colour (Henthorn, et al, 1988).
Reagents :
DEA buffer : 20 ml diethanolamine
10 mg MgCl2
20  mg sodium azide
Made to 100 ml with water, pH to 9.85 with 
conc. HCI, stored in the dark at 30 °C.
Substrate stock solution : PNPP sigma 104 phosphate substrate.
(a) A 0.1 M solution was made in DEA buffer.
(b) This was stored in glass bottles in 3-5 ml 
aliquots in the dark. (Discarded if the
solution turns yellow).
TBS : 154 mM NaCI 
50 mM Tris pH 7.5 
1 mM MgCl2
Reaction mixture : Dilute substrate stock 1:20 jus t before use
(5 mM PNPP).
Method :
(1) Cells were transfected and centrifuged, 800 rpm, 5 min.
(2) The pellet was washed with 1 ml TBS, and transferred to an eppendorf.
(3) A fte r cen trifuga tion  at 10,000 rpm for 5 min, the pe lle t was 
resuspended in 100 |oJ TBS pH 7.8.
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(4) The lysate was prepared by the freeze-thaw method as for adherent 
ce lls .
(5) Heat inactivation was carried out at 65 °C for 30 min.
(6 ) A fter cooling to room tem perature, 20 |il of lysate was added to 
400 \i\ of reaction m ixture, and incubated at 37 °C  for 30-60 min (or 
longer to get measurable activity).
(7) The O.D. was read at 405 nm.
Endogenous PAP activity is absent from a large number of cell lines so far 
tested.
2.35 Phase extraction CAT Assay
Reagents and materials :
0.01 |u,Ci/(xl 3H -ch lo ram phen ico l 
5 mg/ml butyryl CoA 
100  mg/ml unlabelled chloramphenicol 
2 M Tris.CI pH 8.0
2:1 (vol/vol) tetram ethylpentadecane (TM PD)/xylenes
S c in tilla tion  flu id
Procedure:
(a) Preparation of 0.01 jxC i/fil 3H -ch lo ram phen ico l so lu tion  fo r phase 
extraction assay.
(1) A 0.2 |iC i/fil 3H-chloramphenicol stock was prepared by adding 960^1 of 
100% ethanol and 40|xl of 100mg/ml unlabelled chloramphenicol to 250(xl 
of 3H-chloramphenicol (250 |xCi/250|xl in ethanol : 42.0 to 58.2 Ci/mmol).
(2) The 0.2 ( iC i/ | i l 3H-chloram phenicol stock was preextracted by firs t 
diluting it 2 0 -fold in water, and then extracting th is m ixture w ith an 
equal volume of xylenes by vigorous shaking. The sample was centrifuged 
for 2 min at room temp and the top xylenes phase removed and discarded. 
This extraction was repeated once more, creating a working solution of 
0.01 nC i/|il 3H -ch lo ram phen ico l.
(b) Phase extraction CAT assay.
(1) Transfected cells were harvested in PBS and resuspended in 100^.1 ice 
cold 0.25 M Tris.CI pH7.5.
(2) Cells were lysed by four successive cycles of freezing and thawing 
(dry ice/ethanol 5 min, 37°C 5 min.)
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(3) The lysate was then spun for 5 min and the supernatant was removed 
and saved (this is the extract that contains the CAT enzyme).
(4) The lysate was heat treated at 65°C for 10 min to inactivate potential 
in h ib ito rs .
(5) To assay 30fxl of cell extract, the following reaction mix was made per 
sample :
20jxl 0.01 |iC i/|il 3H -ch lo ram phen ico l 
5(il 5mg/ml butyryl CoA 
5(xl 2M Tris.Cl pH 8.0 
40fil H20
(6 ) For each assay 30(il of cell extract was added to 7 0 |il CAT assay mix. 
The samples were incubated for 30 to 90 min at 37°C.
(7) The acety la ted  ch loram phenico l was extracted w ith 2 0 0 |il of 2:1 
TMPD/xylenes by vigorous shaking, fo llowed by centrifugation. The top 
organic phase was removed to a scintillation vial.
(8 ) 3 to 5 ml of scintilla tion flu id was added to each sample and the 
samples were counted to determine CAT activity.
2.36 CAT ELISA
The procedure was fo llowed exactly  as outlined in the Boehringer 
Mannheim CAT ELISA kit instructions. The substrate enhancer was used in 
this case.
P rin c ip le
The ELISA is based on the sandw ich-enzym e im m unoassay principle. 
Antibodies to CAT (anti-CAT) are prebound to the surface of a m icrotitre 
plate. Following lysis of the transfected cells, the cell lysates containing 
the CAT protein are added to the m icrotitre plates. A fte r washing, a 
digoxygenin-labelled anti-CAT is added, followed by an anti-d igoxygenin- 
peroxidase conjugate. The activ ity  of the peroxidase enzyme is then 
assayed by the addition of a co lo rim etric  substrate, and subsequent 
absorbance measurement.
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Principle of the CAT ELISA.
Microtitre plate 
wells precoated with 
anti-CAT
T
Addition of cell lysates 
from transfected cells - 
binding of CAT © to  
the anti-CAT antibodies
Addition of anti- 
CAT-DIG
Addition of anti-DIG- 
peroxidase
Addition of peroxidase 
substrate I  with 
production of a coloured 
product
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2.37 Biorad Protein Assay
Principle of assay :
This assay is based on the observation that the absorbance maximum for 
an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm 
to 595 nm when binding to protein occurs. The method used was an 
adaptation of the Biorad Microassay procedure.
(1) The samples and standards were diluted to 160 | il with water and 
added to 40 \i\ of undiluted dye reagent.
(2) The samples were mixed by gentle vortexing, avoiding excess foaming.
(3) After a period of 5 min to one hour the OD5g5 was read versus a
reagent blank, using an ELISA plate reader.
(4) The OD5g5 was plotted versus concentration of standards, and the 
sample concentrations were read from the standard curve.
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3. Results and Discussion.
3.1 Construction of a CD23 reporter plasmid.
The most common reporter gene used in transfection studies is CAT 
(chloram phenicol acetyl transferase). This enzyme is usually assayed 
using a radioisotopic method. To obviate the need to use a radioassay, we 
constructed and tested a reporter plasm id involving the CD23 promoter 
cloned upstream of PAP (placental alkaline phosphatase). This is a heat 
stable enzyme - the assay involves a co lorim etric reaction, and is a 
simpler and cheaper alternative to the CAT assay.
Two cloning strategies were investigated for pCD23Pap:
Cloning strategy (1)
(a) pSVaAPap was used as the source of the PAP gene.
(b) pBCD23 was used as the source of the CD23 promoter.
(c) pGem3Zf was used as the cloning vector.
Eco RI 555 
Bam HI 53;
(a)
Amp
Ba
Hind ll-Bam HI 
fragment of the 
CD23 promoter 
cloned intoPAP gene under the 
control of the SV40 
promoter -335
pBlueskript SK
+80
EcoRI
Bam HI Hind II
Figure 4. Plasmids used in cloning strategy 1
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Figure 5 : STRATEGY 1 :
Amp
Amp
-335
Amp
Sal I 674
Bam HI 1085
Eco Rl 
Sac I 
Kpn I 
Ava I 
Sma I 
Bam HI 
Xba I 
Sail 
Acc I 
Hindi 
Pst I 
Sph I 
Hind III
Digestion :
Bam HI 
Sal I
Digestion
Bam HI 
Sal I
-335
Bam HI
+80
I
Bam HI
CD23 promoter 
fragment
SaM
Amp Bam HI
Digestion
Bam HI 
Hind III
+80
Sail
Hind III
Hind III
Digestion :
Sal I 
Hind III
Hind III 348
Amp
Digestion :
Bam HI
S a il Sal 15555
Ligation Bam Hi 5331
Hind III
Bam HI
Amp R
Sail
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Strategy (1) (fig. 5) : summary
(a) Sub-cloning the CD23 promoter fragment
pBCD23 was digested with Bam HI and Sal I to excise the CD23 promoter
-335 +80
Bam HI
CD23 promoter 
fragment
Sal
Figure 6.
This fragment was then subcloned into pGem3Zf digested with Bam HI and 
Sal I. This step created a construct conta in ing the CD23 prom oter 
fragment flanked with a number of useful restriction sites :
(b) Cloning PAP downstream of CD23
pBCD23 was then used as the source of the CD23 promoter. A Bam Hl- 
Hind III digestion excised the CD23 fragment. pSV2APap was the digested 
with Hind III and Sal I to isolate the PAP gene. A three fragment ligation 
was carried out with pGem3Zf (digested with Bam HI and Sal I) :
Figure 8. pG3CD23Pap
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Procedural comments :
(1) Double digests of vector were prepared as follows :
After digestion with the first enzyme, the vector was phenol/chloroform  
extracted and ethanol precipitated. This allows buffer conditions to be 
changed for the second digest. A sample was run on a 1% agarose gel to 
ensure digestion was complete before the subsequent digest was carried 
out.
(2) The insert was prepared by double-digestion, fo llowed by isolation 
from a seakem  agarose gel (1.5% ) by sp in-x colum n centrifugation  
(Materials and methods section 2.15).
(3) The following controls were included in the ligation :
(a) Single-digested pGem3Zf (50 ng) +/- ligase.
(b) Double-digested pGem3Zf (50 ng) +/- ligase.
A comparison of these samples indicates if the double-digestion has been 
efficient. The restriction enzymes used have incom patib le ends and so 
should not support ligation in a vector that has been successfully digested 
with each.
The single-digested vector gave a >100 fold increase in the number of 
colonies produced a fter ligation. The double-d igested vector gave no 
s ign ifican t d iffe rence  in co lony num bers before  and a fte r liga tion  
indicating successful double-d igestion.
The competency of the cells was tested when they were made and was 
found to be >107 cfu/jxg DNA.
Analysis of pG3CD23:
i
HI
II
I
IM Figure 9.
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The use of pGem3Zf allows blue/white selection of recombinants. 
Cloned inserts interrupt the lac Z gene which codes for p -ga lac tos idase . 
Production of this enzyme gives rise to blue colonies on plates containing 
the chromogenic substrate x-gal. Recombinants can be selected as white 
colonies.
This cloning creates a construct with a Hind III site at the 3’ end of 
the CD23 promoter fragment of interest (fig. 9). This can then be isolated 
with a Bam Hl-Hind III digest. Clones were analysed by using this digest (a 
Bam Hl/Hind III digest of the pBCD23 parent would linearise the plasmid 
as there are no Hind III sites present). Hinf I digests were also carried out 
for confirm ation.
Predicted sizes of fragm ents from a Hinf I d igest (from  
sequence information) :
pGem3Zf : 1382, 517, 452, 396, 244, 75, 65, 46, 22.
pG3CD23 : 1382, 552, 517, 452, 396, 137, 75, 65, 22.
(differences in the banding patterns are highlighted in bold type).
Approximate sizes of fragments observed on a 1.5% agarose gel :
pGem3Zf 1382, 517, 452, 396, 244.
pG3CD23 1382, 552, 517, 452, 396, 137.
(gel not shown).
The above results show that the fragm ents expected from a digest of 
pG3CD23 were observed indicating the cloning had been successful. The 
bands smaller than 137 bp were not seen due to the limited resolution of 
the gel.
Predicted sizes of fragm ents from a Bam Hl/Hind III digest 
(from sequence information) :
pGem3Zf 3199.
pG3CD23 2919, 411.
1.5% agarose 
Lane : Sample :
1 Molecular weight markers
2 3000 bp marker
3 -7  Isolated colonies A,B,C,D,E
(Bam Hl-Hind III digest).
1 2 3 4 5 6
The gel (fig. 10) shows the expected banding pattern for pG3CD23 digested 
with Bam HI and Hind III (2919, 411 bp).
Analysis of pG3CD23Pap
Figure 10 : Restriction analysis of
Several attempts were made to construct this plasmid, but in all cases 
the three fragment ligation resulted in very few colonies (<30) and of 
these only 10% were white. None of those tested were found to be the 
required plasmid.
The ligase activity was tested by digesting plasmid DNA with a frequently 
cutting enzyme and religating. The result was (a) viewed on a gel before 
and after ligation, and (b) transformed (10 ng).
Transformation gave greater than a 100 fold increase in colonies after 
lig a tio n .
From the 1% gel (fig. 12) it appears the ligase is working.
1
2
3
Figure 12 : Analysis of ligase activity
Lane : Sample :
Molecular weight markers 
Plasmid DNA digested with Hae III. 
Ligation of Hae III digest.
1 2 3
As can be seen from the gel, the DNA bands have all moved to high 
m olecular weight bands in the ligated sam ple indicating ligation was 
successfu l.
The cells were tested for competency and found to be >108 cfu/fig.
Ligations were run on a 1% gel and the DNA before ligation appeared as 2 
bands (PAP ~5 kb and CD23 -400  bp) as expected. After ligation the DNA 
appeared as high molecular weight bands (CD23 band disappearing) as 
expected.
However, transform ation produced few colonies, none with the required 
plasmid. An alternative strategy for the construction of this plasm id was 
then employed.
Cloning strategy (2)
(a) pSVaAPap was used as the source of the PAP gene.
(b) pBCD23 was used as the source of the CD23 promoter.
(c) pGem7Zf was used as the cloning vector (fig. 13).
Figure 13.
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Strategy (2) : summary (fig. 16)
(a) Subcloning the CD23 promoter into pGem7Zf.
pBCD23 was digested with Sal I, repaired to create a blunt end, and then 
digested with Bam HI. The CD23 fragment was gel isolated and cloned into 
pGem7Zf (digested with Bam HI and Sma I) : pG7CD23
(b) Cloning PAP downstream of CD23.
pG7CD23 was then used as the vector in the next step. The PAP gene was 
gel isolated as an Eco Rl fragm ent from pSV2APap, and cloned into 
pG7CD23 digested with Eco Rl. The PAP gene orientation was then 
determined by restriction analysis : pG7CD23Pap.
PAP
Figure 15.
Procedural comments :
(a) The CD23 insert was prepared by d igestion with Sal I, repair to 
generate a blunt end (Materials and methods section 2.23) and digestion 
with Bam HI. DNA was purified from seakem agarose as previously 
described.
(b) Any background of single-digested religated vector (pGem7Zf) was 
reduced by digesting the ligation with Hind III before transformation. (Any 
double-digested vector has lost the Hind III site between Sal I and Bam HI 
in the polylinker).
(c) To reduce the background of religated pG7CD23 in the pCD23Pap 
ligation, the vector was treated with calf in testina l phosphatase (CIP) 
before ligation (materials and methods section 2.19).
(d) Controls were as in strategy (1).
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STRATEGY 2 :
I 674
HI 1085
-335 +80
Amp f1 ori
Eco RI
Digestion : Sal I 
Repair & clean 
Digestion : Bam I 
Gel isolate
Xba I 
Xho I 
Eco Rl 
Kpn I 
Sma I 
Cla I 
Hind III 
Bam HI
Bam HI
CD23 promoter 
fragment
t
Ligation
Digestion :
Eco RI
Figure 16.
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Analysis of pG7CD23 :
Blue/white selection was used to isolate a clone containing an insert.
The construct has an Eco Rl site at the 3’ end of the CD23 fragm ent (fig. 
17). As the parent pBCD23 plasm id does not contain th is site, the 
construct can be analysed for an insert using a Bam Hl/Eco Rl digest. Hinf 
I digests were used for confirmation.
Predicted sizes of fragm ents from a Hinf I d igest (from  
sequence information) :
pG7CD23 1129, 517, 452, 396, 3 5 6 ,3 3 2 , 75, 65, 45, 22.
pGem7Zf 1129, 517, 452, 396, 299, 75, 65,34, 22, 11.
pGem3Zf 1382, 517, 452, 396, 244, 75, 65, 46, 22.
Approx. sizes of fragments observed on a 1.5% agarose gel : 
pG7CD23 : 1129, 517, 452, 396, 356.
pGem3Zf 1382, 517, 452, 396.
Figure 18 : Analysis of pG7CD23 recombinants
Lane : Sample :
1 M olecular weight markers
■ B'fc 1, 1
3«M  B
2*34 m
2 pG7CD23-Hinf I digest
1(36 '« ■  _  
H i t  —
3 pGem3Zf-Hinf I digest
i n  —
4 pG7CD23-Bam Hl/Eco Rl ill
2 98
5 pGem7Zf-Bam Hl/Eco Rl a t
1 2 ) 4 5
As can be seen from the gel, the clone contains the expected Bam HI/ 
Eco Rl fragment (CD23 insert -424 bp).
This was confirmed by the Hinf I digest - fragments were as expected.
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In order to clone PAP downstream of the CD23 promoter, the next step 
involved using the pG7CD23 clone as a vector. The pG7CD23 clone 
(maxiprep) was digested with Eco Rl and treated with CIP to prevent 
recircularisation. The phosphatase treatm ent was shown to be effective 
by carrying out a ligation of plasmid before and after CIP treatment, and 
analysing the result on an agarose gel. Transform ation of these samples 
showed greater than 100 fold decrease in the number of colonies after CIP 
tre a tm en t.
The PAP insert was isolated from pSVsAPap digested with Eco Rl and 
purified by column chromatography as previously described.
Detection of pG7CD23Pap clones
As the vector already contained the CD23 insert, a blue/white selection i*as 
no longer possible. Ligation produced >500 co lon ies. In sp ite  of an 
apparently effective phosphatase treatment, no clones were isolated from 
60 minipreps, so an in situ colony hybridisation technique was used (see 
section 2.20).
The PAP gene was isolated as before and prepared for use as a probe by 
labelling with digoxygenin. A Bam Hl/Eco Rl digest of pG7CD23, followed
by gel isolation produced CD23 DNA for use as a second probe.
400 colonies were regrown in an ordered array and nitrocellu lose colony
lifts were prepared in duplicate.
A com bination of 2 probes was used to enable e lim ination  of 
anything other than the plasmid of interest. A PAP probe would detect the 
clone of interest pG7CD23Pap, but it would also detect the PAP parent 
pSVaAPap. A CD23 probe would detect the clone of interest, but also the 
CD23 parent pG7CD23. Only the clone of interest would give a positive 
result with both probes. Bacteria transformed with pSV2APap or pG7CD23 
were used as controls. An example of a duplicate filter detection is shown 
below :
A
Filter 1 : probed with PAP
a : pG7CD23 
b : pGem7Zf 
c : pSV2APap 
d : clones 1-6
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B
C
D
d : clones 1-6
a : pG7CD23 
b : pGem7Zf 
c : pSV2APap
Filter 2 : probed with CD23
The higher background sta in ing in filte r 2 is like ly to be due to 
overdevelopm ent and insuffic ient washing during the antibody detection 
step. As can be seen from the filters, all clones 1-6 are exam ples of 
positive clones as they hybridise to the PAP and CD23 probes. As expected 
the PAP probe does not hybridise to pBCD23 and the CD23 probe does not 
hybridise to PAP DNA. Neither probe hybridises to pGem7Zf DNA. These 
results indicate the probe is specific and cross-hybrid isation is weak.
Figure 19. Analysis of clones :
The following possibilities existed after cloning strategy 2 :
(a) CD23 parent (b) PAP parent
Am|
Bam HI
Eco Rl
Eco Rl
Bam HI
(c) Clone pG7CD23Pap 
(forward orientation)
Bam HI
(d) Clone pG7CD23Pap 
(reverse orientation)
Bam HI
Bam HI
Eco R
Bam HI
co Rl
Bam HI
Eco Rl
Bam HI
co Rl
Amp R Amp R
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Predicted digests (from sequence information)
P lasm id Enzym e(s) Sizes (bp)
pG7CD23 Bam Hl/Eco Rl 2965, 424
pSV2APap Bam Hl/Eco Rl 4512, 2425, 461, 348
pG7CD23Pap(a) Bam Hl/Eco Rl 4 5 1 2 ,2 9 7 0 ,4 6 1 ,4 1 5 ,
224
pG7CD23Pap(b) Bam Hl/Eco Rl 4 5 1 2 ,2 9 7 0 ,4 6 1 ,4 1 5 ,
224
PG7CD23 Bam HI 3389
pSV2APap Bam HI 4512, 2650, 800
pG7CD23Pap(a) Bam HI 4512, 3200, 876
pG7CD23Pap(b) Bam HI 4512, 3410, 636
Fragments observed on 1.5% agarose gel (Bam HI digests):
pSV2APap
pG7CD23Pap
pG7CD23Pap
4512, 2650, 800 
4512, 3200, 876 
4512, 3410, 636
Figure 20 : Restriction analysis of pG7CD23Pap recombinants
Lane :
1
2
3
4
5
6
7
8
Sample :
Molecular weight markers 
pG7CD23Pap(a)(forward orientation clone)-Bam HI digest 
pSV2APap - Bam HI digest 
Clone 9 Bam HI digest 
Clone 10 - Bam HI digest
pG7CD23Pap(b)(reverse orientation clone)-Bam HI digest 
Clone 12 Bam HI digest 
Molecular weight markers
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As can be seen from the gel (fig. 20), clones were isolated with the PAP 
gene cloned in both orientations. This was confirmed by a digest with Sac 
I- the three plasmids (pSV2APap, pG7CD23Pap(a), pG 7CD23Pap(b)) gave 
different banding patterns when cut with this enzyme.
Figure 21 : Restriction analysis of pG7CD23Pap
Lane
1
2
3
4
5
6
4072 bp-> 
3054 bp->
2036 bp->| 
1636 bp->
1018 bp-> 
517 bp->
Sample :
Molecular weight markers 
pSV2APap - Bam HI digest
pG7CD23Pap(a)(forward orientation clone)-Sac I 
pG7CD23Pap(b)(reverse orientation clone)-Sac I 
Clone 8 - Sac I digest 
Molecular weight markers
digest
digest
The forward clones were now suitab le fo r CD23 prom oter assay by 
transfection . Subsequent ana lys is  of these c lones by tra ns fe c tio n  
however, gave no detectable activity (section 3.5). Further studies on the 
CD23 prom oter were therefore conducted using CAT as the reporter 
enzyme.
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3.2 CD23 prom oter studies part 1: Deletion m utagenesis of
CD23CAT
To investigate the active regions of the CD23 promoter, a set of 
nested de le tion  m utants of the p lasm id pC D 23C AT (fig . 22) was 
constructed. This plasmid contains CD23 (Bam H l-Xho I fragm ent from 
pBCD23) and CAT (Xho l-Nsi I fragment) cloned into pBlueskript SK 
digested with Bam HI and Pst I (Stratagene). The nuclease BAL 31 was 
used for progressive deletion of the promoter in a time course reaction. 
BAL 31 Nucleases
BAL 31 nucleases are extrace llu la r nucleases purified from the 
cu ltu re  m edium  of A lte ro m o n a s  e s p e jia n a  BAL 31. They are 
m u ltifu n c tio n a l enzym es e x h ib it in g  a h ig h ly  s p e c if ic  s tra n d e d  
endodeoxyribonuclease activity which simultaneously degrades both 3’ and 
5’ termini of duplex DNA without internal strand scission. Most of the DNA 
fragments generated have fu lly base paired ends but a fraction has 5 ’ 
generated p ro trud ing  s ing le  strands, ind ica ting  tha t BAL 31 acts 
sequentia lly as a 3 ’ to 5 ’ exonuclease fo llow ed by endonucleolytic 
removal of the protruding strand. Activity is absolutely dependent on the 
presence of calcium and therefore the reaction can be stopped by the 
addition of the chelating agent EGTA.
Xho I 668
Figure 22 : pCD23CAT
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The structure of the pCD23CAT plasmid was first confirm ed by restriction 
analysis.
Enzyme Predicted fragm ents  
(bp)_ _
Hinf I 1 07 7 ,952 ,616 ,517 ,456 ,
3 9 6 ,3 69 ,3 03 ,10 9
Cla I 33 7 5 ,16 8 9
Xho I 3 33 0 ,17 3 4
Eco Rl 3 3 6 9 ,14 1 5 ,2 8 0
Bam HI 2 97 9 ,20 8 5
Xba I 5064
The fragments observed on a 1% agarose gel were as expected (fig. 23).
Figure 23 : Restriction analysis of pCD23CAT
Lane : Sample :
1 Molecular weight markers
2 Uncut pCD23CAT 200 ng
3 pCD23CAT - Hinf I
4 pCD23CAT - Cla I
5 pCD23CAT - Xho I
6 pCD23CAT - Eco Rl
7 pCD23CAT - Bam HI
8 pCD23CAT - Eco RV
9 Partial digest - markers
1 0 Molecular weight markers
4072 bp-> 
3054 bp-> I 
2036 bp-> 
1636 bp->
1018 bp->
517 bp-> 
220 bp->
X  I+ S  <o -=h&  °l IO
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Construction of deletion mutants : summary (fig. 24).
(a) pCD23CAT was digested with Xba I to linearise the plasmid at the 5 ’ 
end of the CD23 promoter.
(b) The linear DNA was digested with BAL 31 nuclease in a time course 
reaction, w ith sam ples being rem oved at appropria te  in te rva ls  and 
quenched with 20 mM EGTA .
(c) Samples of each time point were analysed by digestion with Xho I and 
viewed on an agarose gel. This digest cuts at the 5 ’ and 3’ ends of the CAT 
gene giving 3 fragments : the CD23 fragment, the CAT gene and the vector 
fragment (the CD23 and vector bands should decrease in size as digestion 
proceeds from both ends of the linear DNA, while the CAT band remains 
constant).
(d) The tim e points of in terest were repaired to create  b lunt ends, 
followed by digestion with Bam HI. This cuts out the fragments containing 
the CD23CAT fragment for subcloning. These can then be cloned into either 
pGem7Zf or pBlueskript SK (digested with Bam HI and Sma I).
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Figure 24 : BAL 31 Deletion Mutagenesis
Amp R Xho I 668 Bam HI 734
* f a l _
Bam HI
CAT CD23Xba I digestion CAT
Xba I?
Eco RI 2116 
Xba I 2831 Xho I 2402
Xho I IBAL 31 digestionXho I/Bam HI
.— ►I h
CD23 CAT k
Diges
Xho I
(1)
Xho I digestion to monitor 
time course progression^
Deleted CD23
CD23
Xho I
(2)
(3)
Xho I
> CAT
Xho I/Bam HI
t ! _____ Deleted plasmid
ion
(a) Repair to create
blunt ends
(b)Bam HI digestion
Bam HI
Deleted CAT [>
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Results
1. Analysis of enzyme activity.
Preparations of BAL 31 show considerable va riab ility  in activ ity, 
depending on batch, length of time stored, supplier etc. The CD23 promoter 
fragment of interest is 415 bp in length (-335+80) so the time course 
reaction should allow digestion to the extent that would give less than 
415 bp digested (otherwise the deletion would have proceeded into the 
start of the CAT gene, rendering the construct useless for prom oter 
analysis).
The activ ity of the BAL 31 preparation was analysed by using a 
series of enzyme d ilu tions and time points. The neat preparation of 
enzyme (1 U/jxl) gave an activity that was too high - as can be seen from 
the gel (fig. 25) after only 5 min approx. 800 bp had been digested.
Figure 25 : Analysis of BAL 31 enzyme activity.
Lane : Sample :
1 Molecular weight markers
2 Molecular weight markers
3 Time point 0 min - Bam HI digest
4 Time point 5 min - Bam HI digest
5 Time point 15 min - Bam HI digest
6 Time point 30 min - Bam HI digest
4072 bp->
2036 bp-> 
1636 bp->
The Bam HI digest gave 2 fragments : the CD23CAT fragm ent and the 
plasmid fragment (undigested at T = 0 min).
The dilu tion of enzyme selected was 1/10 (0.1 U/jo.I) w ith time 
points T = 0, 10, 20, 30, 40, 50 min. 2|il of diluted enzyme was used in 
each time course reaction.
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Figure 26 : BAL 31 time course reaction
Lane : Sample :
1 M olecular weight markers 2036 bp->
2 Time point 0 min - Bam HI digest i636bp->
3 Time point 10 min - Bam HI digest
4 Time point 20 min - Bam HI digest
5 Time point 30 min - Bam HI digest
6 Time point 40 min - Bam HI digest
7 Time point 50 min - Bam HI digest
8 Molecular weight markers
The CD23CAT fragm ents from each tim e point were gel purified fo r 
cloning into pGem7Zf (Bam Hl-Sma I digested). Several methods were used 
for gel purification of the insert : spin-x column chrom atography from 
Seakem agarose, electroelution and low melting point agarose.
Ligation results :
1. Transform ation of 100 ng pGem7Zf (Bam Hl/Sma I digest) showed 
greater than 100-fold increase in the number of blue colonies recovered 
after ligation.
2. pGem7Zf (Bam Hl/Sma I digest) was ligated to gel isolated time course 
DNA. Of the resulting transformants, 50% were white.
3. Distilled water was used as the negative control.
Controls :
(1) Transformation control : uncut pGem7Zf (50 ng) gave blue colonies as 
expected when plated on media containing x-gal.
(2) Repair control : pGem7Zf (Bam HI digested, repaired and ligated) - if 
the repair was successful this plasmid when transform ed and plated on 
media containing x-gal, should show increased white colonies after repair. 
A 4-5 fold increase in colony number was observed after repair.
(3) Ligation controls: (a) Cohesive - pGem7Zf (Bam HI digested) +/- ligase.
(b) Blunt - pGem7Zf (Sma I digested) +/- ligase.
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Both samples showed greater than 100 fold increase in the number of 
colonies after ligation.
(4) Cloning control : Hinf I digested pGem7Zf repaired and ligated into 
pGem7Zf digested with Sma I should result in clones with inserts of 
varying sizes.
A fter ligation and analysis of the white transform ants it was found that 
20% contained inserts.
Figure 27 : Analysis of clones :
Eco RI 2396
Amp
Bam HI
Sac I
Xba I 
Xho I 
Eco RI 
Kpn I 
Sma I
Digestion with Eco Rl shows if an insert is present and distinguishes 
between clones and the parent plasmid pCD23CAT (fig. 27).
P lasm id Expected fragm ents from  an 
Eco Rl digest (bp)
pGem7Zf 3000
pCD23CAT 3369, 1415, 280
Clones 4316, 280, <411 (depending on the 
extent of digestion)
XbaI XhoI
Figure 28.
Digestion with Xba l/Xho I allows direct comparison of the insert sizes to 
the CD23 fragment from pCD23CAT (fig. 28) and thus shows the extent of 
de le tion.
Plasm id Expected fragm ents from  an 
Xho l/Xba 1 digest
pGem7Zf 3 kb
PCD23CAT 3 kb, 1.7 kb, 429 bp
Clones 3 kb, 1.7 kb, < 429 bp (depends on 
the extent of deletion)
Transformants were analysed by miniprep of DNA, followed by restriction 
analysis.
Figure 29 : restriction analysis of putative deletion mutants
Lane : Sample:
1 Molecular weight markers ,
2 uncut pCD23CAT
3 miniprep a - Eco RI digest
4 miniprep b - Eco RI digest 3054bp->
5 pCD23CAT - Eco RI digest 1636bP->
6 miniprep c - Eco RI digest 5i 7 bp->
7 miniprep d - Eco RI digest
8 molecular weight markers
As can be seen from the gel (fig. 29), most of the white transform ants 
analysed were due to the parent plasmid pCD23CAT. This appears to have 
been carried over in the gel iso lation step in trace am ounts, and 
transform ed very e ffic iently.
Several attempts were made to clone the time points but despite 
screening over 200 colonies by m iniprep, only one clone was isolated 
(miniprep 48).
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Figure 30 : Restriction analysis of deletion mutant CD23CAT51
2
3
4
Lane : Sample :
PCD23CAT - Xho l/Xba I 
miniprep 27 - Xho l/Xba I 
miniprep 48 - Xho l/Xba I 
Molecular weight markers
» x  3 t;
517/506 bp
3054 bp 
1636 bp
220 bp
The expected size of the CD23 fragment from the parent plasm id in this 
digest is 429 bp. In clone 48 the insert size appears approx. 220 bp. This 
indicates a deletion of approx. 200 bp (CD23CAT51). A deletion of this size 
would remove both of the EBNA-2 responsive elem ents upstream of the 
prom oter.
This would be expected to render the cons truc t un respons ive  to 
transactivation by EBNA-2 (see transfection results 3.5).
Given the unsatisfactory yield of deletion constructs using th is method, 
an alternative was employed.
3.3 CD23 promoter studies part 2: Cloning by PCR 
Objective :
The objective was to PCR amplify specific CD23 promoter sequences for 
insertion upstream of the CAT gene for use in transfection experiments. 
The activity of the promoter fragments in these constructs could then be 
measured by co-transfection with plasm ids encoding EBNA-2/EBNA-3, 
followed by assaying for CAT. Promoter sequence elements e.g. the EBNA-2 
responsive elem ents could also be am plified and cloned upstream  of 
heterologous promoters in CAT vectors and the level of activ ity measured 
to examine the effects of these sequence elements.
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Overall Strategy :
The first step was the construction of a suitable CAT vector i.e. a plasmid 
containing the CAT gene flanked with restriction sites useful for cloning. 
This was achieved by subcloning the CAT gene into pGem7Zf as a Hind III 
fragment - pG7CAT. This results in a construct containing the CAT gene 
flanked by Bam HI and Sma I sites. The primer pairs designed to amplify 
the CD23 prom oter sequences carry restriction enzyme sites at the ir 5 ’ 
ends to facilita te cloning (Sma I and Sac I). Using the double-digested 
vector pGem7Zf (Bam Hl-Sac I), a three-fragm ent ligation was carried out 
to clone CD23 (Sma 1-Sac I) upstream of the CAT gene (Sma l-Bam HI) (fig. 
36).
Strategy step 1: cloning CAT as a Hind III fragment
(1) pGem7Zf was used as the cloning vector (digested with Hind III). The 
vector was treated with CIP to prevent recircularisation.
(2) A plasmid which contains CAT cloned downstream of EBV DNA was 
used as the source of the CAT gene. The insert was prepared as a Hind III 
fragment and isolated from low melting point agarose.
Figure 31 : Construction of pG7CAT
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Figure 32 : Gel isolation of CAT gene
Lane : Sample :
1 M olecular weight markers
2 uncut pGem7Zf
3 -5 pGem7Zf - Hind III digest
6 uncut CAT plasmid
7, 9, 10 CAT plasmid - Hind III digest
3054 bp-> 
1636 bp->
Ligation results :
After ligation of the vector and CAT insert, 20% of the transform ants 
were white and of these, 12 were selected for restriction analysis.
Predicted fragments from restriction digestion (bp) :
Plasm id Hind III Eco RI Rsa 1
pGem7Zf 3000 3000 1821, 1179
CAT plasmid 8279, 1708 5100, 4606, 281 2654, 2095,
1225, 708, 676, 
567, 538, 425, 
400, 260, 224, 
215.
pG7CAT clone 3000, 1708 4429, 279. 2133, 1179, 708, 
538, 150.
Figure 33 : Analysis of recombinant pG7CAT clones 
Lane : Sample :
1 Markers
2 uncut pGem7Zf
3 uncut CAT plasmid
4 pGem7Zf - Hind III
5 -9  pG7CAT minipreps - Hind
1 0 CAT plasmid - Hind III
1 1 pGem7Zf - Hind III
9 5
3054 bp->
1636 b p - >
As can be seen from the gel (fig. 33), the pG7CAT m inipreps showed the 
expected insert at 1.7 kb.
Figure 34 : Restriction analysis of pG7CAT clones
Lane: Sample :
1 M arkers
2 pGem7Zf uncut
3 CAT plasmid uncut 4072 bp-
4 pGem7Zf - Rsa I
5 - 9 pG7CAT minipreps - Rsa I 2036 bp~>
10 CAT plasmid - Rsa I 1636 bp
11 M arkers 1018 bp->
*3 ^ IQ il
Five clones were isolated (fig. 34) - four in the desired orientation (lanes 
6-9) and one in the reverse orientation (lane 5).
The Rsa I digest for the reverse clone gave a different banding pattern to 
the forward clones which were all the same.
Figure 35 : Restriction analysis of pG7CAT
Lane : Sample :
1 Markers
2 pGem7Zf - Eco Rl 3054 bp
3 pG7CAT - Eco Rl
3 9 6  b p -
9 6
Cloning Strategy step 2: cloning CD23
CD23 promoter sequences were PCR am plified using prim er pairs with 
Sma I and Sac I sites at their ends and cloned upstream of CAT (fig. 36).
Figure 36 : Construction of CD23CAT plasmids
Sac I Sma I
CD23
(a) Digest pG7CAT with 
Bam HI and Sma I to 
excise the CAT gene
Sma I ^
1
CAT
(b) PCR amplify CD23 
fragment of interest.
Digest with Sac I and Sma I
Bam HI
(c) Clone these fragments 
into pGem3Zf digested with 
Bam HI and Sac I
Sac I
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CD23 sequence (Suter, et at. 1987):
-3 3 2
GATCCCAACTCCAGGCCGTCCTTCTAACCCAAGAGGCCCTGCCTCTGCCT
AGAGCCTTCCGTGGCTCCCCAGGGCCCTCTGTGATCGGCCATAGTGGTATGATT
(S/^¥(il¥(§CAGTAACAGTGGTTCACATCTTGACGCTACCACTCACCTCCTTCAG
C(SC T^T^^a^(S¥T^(STG C TTA ACATCTCTAGTTCTCACCCAATTCTCTT
ACCTGAGAAATGGAGATAAAATAACACGGACTTCACCGGGTGTGGGGAGCACCAGG
AGAGGCCATGCGTGTAATGTTATCCGGGTGGCAAGCCCATATTTAGGTCTATGAAA
ATAGAAGCTGTCAGTGGCTCTACTTTCAGAAGAAAGTGTCTCTCTTCCTGCTTA
AACCTCTGTCTCTGACGGTCCCTGCCAATCGCTCTGGTC
+81
EBNA 2 Responsive Elements :
(D©T(§T(§ d ©
Primer sequences are in bold type and underlined.
Figure 37 : Location of primers on the CD23 promoter sequence
EBNA 2 responsive elements 
For primer sequences see materials and methods section 2.21. 
Figure 38 : PCR amplification of CD23 j
Lane : Sample :
1 M olecular weight markers
2 CD23 PCR - primers 1+4
3 CD23 PCR - primers 1+5
4 CD23 PCR - primers 3+5
5 CD23 PCR - primers 2+5
6 M olecular weight markers
98
400 bp-: 
300 bp->
2 0 0  bp->
Figure 39 : PCR amplification of CD23
Lane : Sample :
1 Molecular weight markers
2 CD23 PCR - primers 2+4
Primer com bination Expected product size (bp)
1 and 5 312
1 and 4 132
2 and 5 266
2 and 4 85
3 and 5 206
The gels show (fig. 38 and 39) that the sizes of the fragments obtained by 
PCR amplification of CD23 were as expected.
The vector pGem3Zf was digested with Bam HI and Sac I to clone the PCR 
products and the CAT gene.
The CAT insert was prepared by digesting pG7CAT with Bam HI and Sma I 
followed by a gel isolation.
The PCR products were gel isolated and digested with Sac I and Bam HI.
Ligations were set up for each of the PCR products w ith controls as 
before:
No white colonies were observed in any case.
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Although th is experim ent was repeated several tim es, no white 
colonies resulted. A possib ility  for the fa ilure of th is experim ent was 
tha t the d igests of the PCR products were not successfu l (some 
restriction enzymes such as Sal I fail to cut when they are close to the 
ends of a DNA molecule). To investigate this possibility, the PCR products 
were digested with both enzymes - Sma I and Sac I - individually, and run 
on a high percentage agarose gel (3.5%) to compare the sizes with the 
products before restriction.
Analysis of the published sequence for the CD23 promoter (Suter, et al,
1987) showed there should be no internal Sma I site in this sequence. 
However, d igestion of the PCR products with Sma I contradicted this 
observation (fig. 40).
Figure 40 : Restriction analysis of PCR products
3.5 % agarose.
Lane : Sam ple:
1 M olecular weight markers
2 PCR product (primers 1+4)
3 PCR product (primers 1+4) - Sma I digest
4 PCR product (primers 1+5)
5 PCR product (primers 1+5)- Sma I digest
6 PCR product (primers 3+5)
7 PCR product (primers 3+5)- Sma I digest
8 PCR product (primers 2+5)
9 PCR product (primers 2+5)- Sma I digest
I 0 PCR product (primers 2+4)
I I  PCR product (primers 2+4)- Sma I digest
1 2 M olecular weight markers
As can be seen from the gel, three of the PCR products appeared to contain 
an internal Sma I site. The other two PCR products were analysed on a 
higher percentage gel and it was noted that Sma I cuts these products as 
expected - with 5 bases cleaved from the ends as expected (not shown).
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The PCR products were also digested with Xma I - th is has the same 
recognition site as Sma I. The same result was observed, elim inating the 
possib ility that the Sma I enzyme preparation was contam inated with 
another enzyme or that samples had been mixed up.
To investigate if this apparent Sma I site was present in the plasmid from 
which the CD23 promoter sequences were amplified i.e. pCD23CAT, this 
plasmid was digested with Sac I and Sma I.
Figure 41. Sma I and Sac I sites in pCD23CAT.
From sequence inform ation the predicted sizes of fragm ents obtained 
from digestion of pCD23CAT (fig. 41) are :
Sma 1 5064
Sac 1 + Sma 1 2934, 1660, 470
If an additional Sma I site is present in the CD23 sequence, the 470 bp 
band would be expected to be replaced by 2 smaller bands.
Figure 42 : Restriction analysis of CD23CAT
Lane : Sample :
1 Markers
2 pCD23CAT uncut
3 pCD23CAT - Xba I
4 pCD23CAT - Sma I
5 pCD23CAT - Sma I/Sac I
6 M arkers
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CD23CAT Analysis 
3 « i l  M  V 3  B r f  Ü  GS> fc .
I'“:! 5090.49?2b| 2 03 6 bp 1636 bp
10l8bp
5 8 6 ,517bp
3 96 bp 
3 44 bp
298bp
2 2 0 ,2 0 1  bp 
1 5 4 ,134bp
1 2 3 4 5 6
As can be seen from the gel (fig. 42), there appears to be an additional
internal Sma I site present in the CD23 sequence of this plasmid. Instead
of linearising the plasmid as predicted, the Sma I digest gave 2 bands, one 
of which was approx. 210 bp. The predicted sizes of the fragments from a 
Sma I/Sac I double digest are 2934 (plasmid), 1660 (CAT).and 470 bp 
(CD23). The fragments observed were : approx. 2.9 kb, 1.65 kb, 280 bp and 
200 bp. This indicates that an additional Sma I site is present in the CD23 
promoter sequence.
As the pCD23CAT plasmid was constructed originally by using a sequence 
amplified by PCR from a B lymphoma cell line (DG75) it is possible that a 
clone was iso la ted  which conta ined a m utation resu lting  from  a 
m isincorporation in the PCR reaction. To investigate this further, genomic 
DNA was am plified from DG75 cells and analysed using restric tion  
d igests.
A rapid method for the isolation of genomic DNA was used : 104 cells 
were pelleted by centrifugation, washed in PBS and boiled in 50|xl of 
distilled water for 15 min. This lysate was then used in the PCR reaction. 
The biggest of the PCR products was amplified from genomic DNA (312 bp 
product amplified using primers 1 and 5).
Figure 43 : genomic CD23 amplification from DG75
2% agarose
Lane : Sample:
3 CD23 amplified from pCD23CAT
4 Negative control - no template
5 Negative control - no primers
6 -8  CD23 amplified from genomic DNA
9 M olecular weight markers
The PCR product from the genomic amplification was then analysed by 
digestion with Sma I, and compared to the results obtained from the PCR 
product from pCD23CAT.
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Figure 44 : Analysis of genomic CD23 PCR products
6
2
3
4
5
Lane : Sample:
Molecular weight markers 
312 bp product from pCD23CAT 
312 bp product from genomic DG75 DNA 
312 bp product from pCD23CAT 
(Sma I digested)
312 bp product from genomic DG75 DNA 
(Sma I digested)
Molecular weight markers
From this gel (fig. 44) it appears that the sequence difference is not an 
artefact of PCR but is also present in the genome of DG75 cells. This 
result was reproducible.
Analysis of results : mapping the location of the potential
sequence mutation.
1 2 3
-332 +814
PCR Products: Primer pairs :
(312 bp) 1+5
1+4
2+5
(132 bp)
^  (266 bp)
I (85 bp) 2+4
X (206 bp)---------- 3+5
Predicted Sma I site
Figure 45.
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PCR products Approx. size of fragments from  
a Sma 1 digest
312 bp 180, 130 bp
132 bp 132 bp
266 bp 130, 130 bp
85 bp 85 bp
206 bp 130, 70 bp
From this restriction analysis it appears that the potential Sma I site is 
located approx. 130 bp from the 5 ’ end of the reverse primer (primer 5). 
Examination of the CD23 sequence at this location reveals this sequence : 
(-92) TCACCGGGTGT (-82). A single base change from A to C, or deletion 
of the A could have generated the observed Sma I site (CCCGGG).
Digestion of the pCD23CAT plasmid confirmed this : the Sma I digest 
yielded fragments approx. 4800 and 210 bp in length. If the theoretical 
Sma I site is present then the digestion of pCD23CAT with Sma I would 
give the following :
Figure 46.
An alternative strategy must be found for cloning the PCR products : 
either by using a T vector or by repairing and cloning into a blunt 
restriction site e.g. the Sma I site of pG7CAT.
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In order to assay the activity of the CD23 promoter in the constructs, co­
transfections with EBNA-2/EBNA-3 were carried out in a range of cell 
backgrounds, including the EBV-negative B u rk itt’s lym phom a cell line, 
DG75. The successful growth of this cell line depends very much on the 
batch of fetal calf serum used to supplem ent the growth medium. To 
establish optimum growth conditions for DG75, a set of serum tests were 
set up.
3.4 Serum tests.
Serum samples from three different sources were used (Gibco, Advanced 
protein products and Hyclone), as well as a sem i-synthetic  substitute 
(Fetal Clone I from Stratagene). RPMI-1640 was supplemented with 10% 
serum in each case and the growth of cells was measured over a week. The 
results are as follows :
Cell number VS Time
— i----------------------1-----------------------1--------------------- 1—
Day 1 Day 2 Day 3 Day 5
 1—
Day 7
Gibco
Advanced protein products
Hyclone
Fetal Clone 1
T im e  
Figure 47.
All subsequent culture of DG75 was carried out in media supplemented 
with 10% serum from Gibco Batch number 40G9635F.
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3.5 Transfections.
To examine the regulation of the CD23 prom oter by EBV latent 
proteins EBNA-2 and EBNA-3A, co-transfection assays were carried out in 
a range of cell backgrounds using the CD23 prom oter-reporter constructs 
and the appropria te  EBNA expression vectors. Each cell line was 
transfected with a plasmid containing the CAT gene under the control of 
the CMV promoter (pCMVCAT). This is the positive control for the CAT 
assay and should be detected in all cell lines transfected (CAT activ ity 
indicating successfu l transfection).
Placental alkaline phosphatase (pSV2APap) was used as the internal 
transfection  con tro l - an in te rna l con tro l func tions  as a pos itive  
indication that transfection has occurred. In samples where CAT activ ity 
is expected to vary (e.g. in the case of EBNA-2 upregulation) it is 
necessary to show tha t any varia tion  is not due to d iffe rences in 
transfection efficiencies between samples. Hence the inclusion of equal 
quantities of PAP DNA in each transfection should indicate the efficiency 
of tran s fe c tion  (if tra n s fe c tio n  e ffic ie n c ie s  betw een sam ples are 
comparable, then the amount of PAP detected should also be comparable).
The plasm ids carrying CAT under the control of the entire and 
deleted CD23 promoter fragments (pCD23CAT and pCD23CAT81) were also 
transfected alone, and in combinations with EBNA 2 and EBNA 3A.
The construct containing the PAP gene under the control of the CD23 
promoter was tested alone, and in combinations with EBNA 2 and EBNA 3A. 
In this case, the internal transfection control used was p-galactosidase.
All harvesting and reporter assays were carried out 48 hours post­
transfection (as outlined in section 2.33). The resulting cell extracts do 
not contain identical numbers of cells and so must be norm alised for 
protein content before analysis. This ensures that any varia tions in 
reporter enzyme expression seen are not due to varia tions in protein 
concentra tions between sam ples, a llow ing sam ples to be com pared 
directly. This is done using the Biorad protein microassay.
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In summary, the results are as follows
(a) Hep G2 cells were found to have an endogenous heat stable PAP 
activity which means pSV2APap cannot be used as a transfection control. 
Attempts to transfect these cells appear to have failed (no CAT activity 
detected from the pCMVCAT control). For this reason, no further research 
was carried out using this cell line.
(b) SW480 cells were successfully transfected (PAP and CAT activities 
detected). No transactivation of the CD23 promoter by EBNA-2 was seen in 
this cell line.
(c) In the T cell lymphoma line, HuT 78, transfection efficiencies varied 
widely between experiments. Successful transfection was achieved in one 
case (PAP activ ity  was detected in transfected  cell extracts). CAT 
activity was seen in the extract from the cells transfected with pCMVCAT 
but no transactivation of the CD23 promoter was apparent in this cell line.
(d) In DG75, EBNA-2 was seen to upregulate CD23 gene expression by a 
factor of 4-5. This effect was repressed by EBNA-3A, with CAT reporter 
enzyme activity returning to the basal levels. The deletion mutant of the 
CD23 prom oter, pCD23CAT81, was not sensitive to transactivation by 
EBNA-2 (this is as expected as this construct is deleted for the DNA 
elements known to be EBNA-2-responsive).
(e) The construct pCD23Pap showed no activity in any of the cell lines 
tested, either alone, or in combination with plasmids expressing EBNA-2.
10 7
Results :
A. Biorad protein assay.
Standard curve :
BSA (ng) O.D. @ 595 nm.
0.00 0.000
1.40 0.102
2.70 0.185
4.10 0.290
8.20 0.495
16.40 0.837
Biorad Protein Assay Standard
o
0 0.25 0.5 0.75 1
Curve
OD @ 595 nm
Figure 48.
Transfections set 1 : Results
The conditions established for the transfection of DG75 were 250jxI of 
cells (107 cells), 30 \i\ (up to 90|xg) of DNA, 220 V, 960 |iF .
Protein Assay : 10^1 cell extract + 150|il water + 40/xl dye reagent.
Samples (plasmids used in each transfection):
A : CD23CAT (40jig) + PSV2APap (20 |xg)
B : CD23CAT (40^ig) + PSV2APap (20 \ig) + 10^g pCMVEBNA2 
C : CD23CAT (40^ig) + PSV2APap (20 ^g) + 10^ig pCMVEBNA2 
+ 20(ig pCMVEBNA3A 
D : CD23CAT (40^ig) + PSV2APap (20 ig) + 20|xg pCMVEBNA3A 
E : PSV2APap (20 jxg)
(pG7CAT was used as carrier DNA in all cases - the total DNA quantity in 
each transfection should be the same)
Sam ple O.D.@ 595 nm Protein (n g /jil)
DG75 A 0.414 0.80
DG75 B 0.211 0.40
DG75C 0.218 0.41
DG75D 0.171 0.34
DG75E 0.338 0.66
HuT 78 A 0.312 0.59
HuT 78 B 0.369 0.72
HuT 78 C 0.347 0.68
HuT 78 D 0.358 0.69
HuT 78 E 0.382 0.73
Hep G2 A 0.242 0.47
Hep G2 B 0.226 0.44
Hep G2 C 0.220 0.44
Hep G2 D 0.190 0.37
Hep G2 E 0.231 0.45
Table 1. Protein concentrations in transfected cell extracts.
10 9
Transfections set 2 : results.
Protein assay : 10 |il of extract + 150^ ,1 of water + 40(xl of dye reagent.
Samples (plasmids used in each transfection) :
1 : pCMVCAT (40|ig) + pSV2APap (20jig)
2 : pCD23CAT (40|ig) + pSV2APap (20^ig)
3 : pCD23CAT (40^g) + pSV2APap (20|ig) + pCMVEBNA2 (10M,g)
4 : pCD23CAT (40^ig) + pSV2APap (20^g) + pCMVEBNA2 (10jxg) +
pCMVEBNA3A (20^ig)
5 : pCD23CAT (40^ig) + pSV2APap (20^ig) + pCMVEBNA3A (20^ig)
6 : pCD23Pap (40^ig)
7 : pCD23Pap (40^ig) + pCMVEBNA2 (10^ig)
8 : pCD23Pap (40|tig) + pCMVEBNA2 (10|j,g) + pCMVEBNA3A (20|xg)
9 : pCD23Pap (40|ng) + pSV2APap (20fig)
10: pG7CAT (90^ig)
(a) DG75
Sam ple O.D. @ 595 nm Protein (jxg/|a. 1)
1 0.202 0.39
2 0.282 0.54
3 0.532 1.00
4 0.244 0.47
5 0.317 0.59
6 0.218 0.41
7 0.195 0.37
8 0.258 0.50
9 0.170 0.34
1 0 0.331 0.66
Table 2. P ro te in  c o n ce n tra tio n s  in cell ex tra c ts  from  
transfected DG75.
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(b) HuT 78
Sam ple O.D. @ 595 nm Protein (jxg/(x 1)
1 0.207 0.39
2 0.196 0.37
3 0.251 0.50
4 0.309 0.59
5 0.471 0.90
6 0.063 0.14
7 0.219 0.44
8 0.310 0.59
9 0.305 0.59
1 0 0.376 0.73
Table 3. P ro tein  co n ce n tra tio n s  in ce ll e x tra c ts  from  
transfected HuT 78.
(c) SW480
Sam ple O.D. @ 595 nm Protein (|xg /jil)
1 0.408 0.79
2 0.411 0.79
3 0.345 1.68
4 0.402 0.79
5 0.430 0.82
6 0.259 0.50
7 0.368 0.70
8 0.455 0.87
9 0.388 0.73
1 0 0 .334 0.66
Table 4. P ro te in  co n ce n tra tio n s  in ce ll e x tra c ts  from  
transfected SW480.
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Transfections set 3 : Results
Protein Assay : 10^.1 cell extract + 150|j.l water + 40jliI dye reagent.
Samples (plasmids used in each transfection):
A : CMVCAT (40^g) + PSV2APap (20 |xg)
B : CD23CAT (40ng) + PSV2APap (20 ng)
C : CD23CAT (40fig) + PSV2APap (20 |ig) + 10|ig pCMVEBNA2
D : CD23CAT (40^ig) + PSV2APap (20 ^g) + 10jxg pCMVEBNA2
+ 20fig pCMVEBNA3A 
E : CD23CAT (40jxg) + PSV2APap (20 |ig) + 20^ig pCMVEBNA3A 
F : pG7CAT (90 jxg)
G : CD23CAT81 (40^ig) + PSV2APap (20 jug)
H : CD23CAT61 (40^ig) + PSV2APap (20 ng) + 10^ig pCMVEBNA2 
(pG7CAT was used as carrier DNA in all cases).
Sam ple O.D.@ 595 nm Protein (|xg /|il)
DG75 A 0.487 0.91
DG75 B 0.511 0.93
DG75C 0.403 0.79
DG75D 0.440 0.82
DG75E 0.387 0.73
DG75F 0.261 0.50
DG75G 0.414 0.80
DG75H 0.461 0.87
HuT 78 A 0.415 0.80
HuT 78 B 0.521 0.99
HuT 78 C 0.444 0.86
HuT 78 D 0.278 0.53
HuT 78 E 0.403 0.79
HuT 78 F 0.388 0.73
Table 5. Protein concentrations in extracts from transfected
c e lls .
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B. PAP Assay
Standard curve (blanked against reaction mixture w ithout enzyme)
Phosphatase (ng) O.D. @ 405 nm
0.00 0.000
0.05 0.126
0.10 0.189
0.15 0.288
0.20 0.398
0.25 0.491
Table 6. PAP assay standard curve.
PAP Assay Standard Curve
Phosphatase (ng) 
Figure 49.
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Transfections set 1 : results.
PAP assay : 10^,1 of extract assayed in each case.
(a) DG75 - no PAP activity detected in any of the samples.
(b) HuT 78
Sam ple O.D. @ 405 nm ng PAP/|ig protein
A 0.144 0 .0047
B 0.160 0 .0102
C 0.300 0 .0189
D 0.100 0 .0074
E 0.000 0 .0000
Table 7. PAP concentrations in cell extracts from transfected  
HuT 78.
(c) Hep G2 : endogenous heat stable activity seen in all samples. 
Transfections set 2 : results.
PAP assay : 20 (il of extract (diluted 1/10) for DG75 samples.
10|il of extract (diluted 1/10) for SW480 samples. 
(a) DG75_____________ _______________________ ______________
Sam ple O.D. @ 405 nm ng PAP/|ig protein
1 0.139 0.089
2 0.168 0.083
3 0.192 0.150
4 0.127 0.069
5 0.210 0.089
6 0.019 -
7 0.018 -
8 0.015 -
9 0.012 -
1 0 0.020 -
Table 8. PAP concentrations in cell extracts from transfected  
DG75.
(b) HuT 78 : No PAP detectable in any of the HuT 78 samples.
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(c) SW480
Sam ple O.D. @ 405 nm ng PAP/fig protein
1 0.283 0.186
2 0.273 0.112
3 0.261 0.228
4 0.253 0.103
5 0.277 0.118
6 0.080 -
7 0.060 -
8 0.030 -
9 0.030 -
1 0 0.080 -
Table 9. PAP conce 
SW 480.
Transfections set 3 : 
PAP assay : DG75 : 20
ntrations in cell extracts from transfectec 
results.
of extract, HuT 78 : 20jxl of extract.
Sam ple O.D.@ 595 nm ng PAP/|tig protein
DG75 A 1.317 0.038
DG75 B 2.344 0.065
DG75C 1.424 0.047
DG75D 0.823 0.026
DG75E 1.833 0.058
DG75F 1.863 -
DG75G 1.907 0.039
DG75H 1.680 0.050
HuT 78 A 0.390 -
HuT 78 B 0.365 -
HuT 78 C 0.429 -
HuT 78 D 0.285 -
HuT 78 E 0.312 -
HuT 78 F 0.337 -
Table 10. PAP concentrations in extracts from transfected
c e lls .
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C. Phase extraction radioassay for CAT.
Samples were counted for 10 min after addition of scintilla tion fluid. 
The background was 16.5 cpm.
The standard (101700 dpm) was read as 24383.0 cpm.
Standard curve :
Units CAT enzyme pg CAT enzyme cpm
0.000 0 2763 .4
0.005 60 4397 .7
0.010 120 6674.9
0.020 240 8024 .0
0.040 480 11582.5
0.060 720 15280.9
Table 11. CAT assay standard curve
CAT Assay Standard Curve
pg CAT
Figure 50.
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Transfections set 1 : results
Samples that had shown positive transfection i.e. PAP activ ity, were 
assayed for CAT.
CAT assay :
30 \i\ samples assayed in each case (each sample normalised to 15 ng of 
total prote in).____________________________________
Sam ple cpm
HuT 78 A 15423.3
HuT 78 B 2027.1
HuT 78 C 1466.3
HuT 78 E 2477.7
Table 12. CAT activity in cell extracts from transfected HuT 78.
Transfection with pCMVCAT gave CAT activity (table 12), but transfection 
with pCD23CAT alone or in combination with EBNA2 gave no detectable 
s ignal.
Transfections set 2 : results 
CAT assay :
30 ^il samples assayed in each case (each sample normalised to 15 |^g of 
total prote in).
(a) DG75
Sam ple cpm
1 15754.7
2 6101.1
3 20574 .7
4 3840.1
5 5749.8
1 0 3758.2
Table 13. CAT activity in cell extracts from transfected DG75.
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DG75 Transfection Assay
O 4 1 (0
<  3 -
0)> 2 -
+-■ 
ra
CC 1
A : pCMVCAT
B : pCD23CAT
C :pCD23CAT+ 
pCMVEBNA2
D :pCD23CAT + 
pCMVEBNA3a
E :pCD23CAT+ 
pCMVEBNA2+ 
pCMVEBNA3a
F : pGemCAT
Plasm ids transfected
Figure 51. DG75 transfection assay 1
(b) SW480
Sam ple cpm
1 14984.9
2 6182.3
3 7510.1
4 2821.6
5 2592.8
1 0 4182.8
Table 14. CAT activity in cell extracts from transfected SW480.
The CMV prom oter appears to be functioning in these cells, giving a 
detectable level of CAT.
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Comparison with ELISA :
The SW480 sample was also assayed using the Boehringer CAT ELISA. The 
radioassay gave a result of 350 pg of CAT when corrected for background. 
The ELISA result for the same sample was 270 pg.
Transfections set 3 : results.
CAT assay :
5(xl of sample for DG75 samples (normalised to 5^g total protein).
5^ .1 of sample for HuT 78 samples (normalised to 5^ig total protein).
Background was 15.4 cpm.
Standard was read as 24406.4 cpm (101700 dpm).
Sam ple cpm
DG75 A 19232.4
DG75 B 234.1
DG75C 870.1
DG75D 246.0
DG75E 257.1
DG75F 232.6
DG75G 244.2
DG75H 238.1
HuT 78 A 275.7
HuT 78 B 271.2
HuT 78 C 204.7
HuT 78 D 227.6
HuT 78 E 301.4
HuT 78 F 266.2
Table 14. CAT activ ity  in extracts from transfected  cells.
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DG75 Transfection Assay
A : pCMVCAT
B : pCD23CAT
C :pCD23CAT+ 
pCMVEBNA2
D :pCD23CAT+ 
pCMVEBNA3a
E :pCD23CAT+ 
pCMVEBNA2 + 
pCMVEBNA3a
F : pGemCAT
Plasm ids transfected  
Figure 52 : DG75 transfection assay 2.
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4. General Discussion i
CD23 is an early, B cell surface antigen marker induced by antigen, 
mitogen or IL-4 stim ulation. All EBV-transformed B lym phocytes express 
high CD23 leve ls, and EB V -im m orta lised  B ce lls  a rise  from  the 
subpopulation of cells expressing CD23 soon after infection (Azim, et al, 
1988). EBNA-2 is essential for B lymphocyte growth transform ation and 
has been shown to specifically upregulate mRNAs encoding CD23 (Wang, et 
al, 1991). Activation of CD23 expression could be im plicated in the 
estab lishm ent of an autocrine  loop of grow th facto rs, the surface 
molecule acting as a receptor, and the processed molecule acting as a 
growth factor (Sarfati, et al, 1984). Hence EBNA-2 upregulation of CD23 
expression is likely to be an important pathway for EBV-induced B cell 
growth transform ation. The purpose of th is  study was to explore the 
regulation of CD23 gene expression by EBV latent proteins.
The basis of one of the most common approaches to promoter study 
is the p lacing of con tro lling  e lem ents such as p rom ote r/enhancer 
sequences from the 5 ’ end of the gene upstream of a reporter gene. 
Reporter enzyme activ ity  is easily assayed, and is usua lly a d irect 
indication of the activity of the upstream element. Deletions or mutations 
can thus be introduced into the promoter region of interest and the effects 
on activity studied by measuring activity of the reporter enzyme.
To facilita te measurement of the activ ity of the CD23 promoter, it 
was first cloned upstream of a suitable reporter gene. The most popular 
reporter used in studies of gene expression is E. coli CAT (chloramphenicol 
acetyl transferase). CAT is usually assayed using a radioisotopic method. 
To avoid the use of radioactive substrates, an alternative reporter was 
investigated. Henthorn et al have reported the use of human placental 
alkaline phosphatase (PAP) as a suitable reporter gene for transfection 
studies. This enzyme can be rapidly assayed using a simple and cheap 
colorimetric assay with a sensitivity comparable to CAT (Henthorn, et al,
1988).
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Two strategies were em ployed for construction  of a CD23PAP 
reporter plasmid (as outlined in section 3.1). The CD23 promoter element 
(-335/+80) was prepared for cloning as th is is the prom oter elem ent 
containing the DNA sequence elem ent shown to be transactiva ted by 
EBNA-2 (Wang, et al, 1991). The resultant clone (prepared by strategy 2) 
was used in transfection studies with plasm ids encoding EBNA-2 and 
EBNA-3 (fig. 53).
Figure 53 : pG7CD23Pap
Investigation of the CD23 promoter active regions was carried out 
by constructing a set of deletion mutants of the prom oter for use in 
transfection studies. Two strateg ies were em ployed : the use of the 
nuclease BAL 31, and the am plifica tion  of se lected regions of the 
promoter by PCR.
The nuclease BAL 31 was used for progressive deletion of the CD23 
promoter in a time course reaction (see section 3.2). The enzyme activity 
was first analysed to enable selection of time points that would give an 
appropriate digestion (as the promoter is 415 bp in length deletions larger 
than this would not be useful). A suitable time course was obtained, 
however subsequent attem pts to clone the resultant de letion mutants 
yielded only one clone. The resulting transformants analysed were found 
to contain mostly the parental pCD23CAT. This plasmid appears to have 
been carried over in the gel isolation steps, and as it is a supercoiled 
plasmid it transform s with a very high effic iency in trace amounts that 
would not necessarily be visible on a gel. The experimental controls also 
showed that the repair step should be modified as it appears to have a low 
efficiency. While the transformation and ligation efficiencies appear high, 
a blunt-ended cloning control showed a low effic iency of transform ants 
with inserts (only 20% of those selected by blue/white screening).
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The deletion mutant isolated (pCD23Pap81) contained a deletion of 
approx. 200 bp (from restriction analysis) - this would remove both of the 
EBNA-2 responsive elements upstream of the promoter and hence should 
render the construct unresponsive to transactivation by EBNA-2. This was 
subsequently analysed in transfection studies.
A second strategy was employed due to the low yield of deletion 
mutants produced by this method. PCR was used to amplify CD23 promoter 
sequence elements of d ifferent sizes for cloning upstream of a reporter 
gene for use in transfection studies. Firstly, the CAT gene was cloned into 
a commercially available cloning vector pGem7Zf to generate a cloning 
vector containing the reporter gene flanked by m ultiple restriction sites. 
This was done to fac ilita te  cloning of the CAT gene and CD23 PCR 
fragm ents in a th ree-fragm ent ligation scheme (Fig. 36). The CD23 
prom oter sequence elem ents were am plified using prim er pairs with
restriction s ites Sma I and Sac I at the ir ends. The sites were 
incorporated into the primers to facilita te cloning of the PCR products 
without the need for a repair step. The enzymes were chosen as they were 
not present internally in the published CD23 sequence (Suter, et al, 1987) 
and were situated upstream of the CAT gene in pG7CAT. Failure to clone 
the PCR products and subsequent analysis led to the discovery of an 
internal Sma I site in the CD23 sequence (see section 3.3). Am plification 
of genomic CD23 from DG75 cells and subsequent restriction analysis
showed that this site is present in genomic DNA and is not an artefact of 
PCR (the CD23 promoter used was orig inally cloned from PCR-amplified 
DNA). Examination of the published CD23 sequence and restriction analysis 
of the PCR products indicated that this Sma I site may be the result of a 
single base change from A to C or deletion of an A (position -90) (see
section 3.3). The CD23 DNA orig ina lly  sequenced and published was
isolated from human placental cells. This apparent sequence mutation 
found may be unique to DG75 cells. To investigate this, genomic CD23 from 
other cell lines should be analysed. However, as genomic DNA isolation 
from other cell lines (SW480, HuT 78) was unsuccessful, PCR could not be 
carried out. The DG75 mutation does not appear to affect the putative 
EBNA-2 responsive element or create any new known sequence elements. 
It was concluded an alternative strategy is needed to clone these PCR 
products - potentially by using T vectors (Marchuk, et al, 1990).
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The objective of these studies was to examine the regulation of the 
CD23 promoter by EBV latent proteins in B cells, and compare the results 
with those obtained in d ifferent cell backgrounds. This was done by
analysis of CAT activ ity from the reporter constructs a fte r transfection 
into a variety of cell lines. The cell lines used were DG75, HuT 78, SW 480 
and Hep G2. Each cell line was transfected with a plasmid containing the 
CAT gene under the control of the CMV promoter. This is the positive 
control fo r the CAT assay and should be detected in all cell lines
transfected. The plasmid carrying the CAT gene under the control of the 
CD23 prom oter was also transfected alone, and in com binations with 
EBNA-2 and EBNA-3A. Placental alkaline phosphatase (pSV2APap) was 
used as the transfection control. The construct containing the PAP gene 
under the control of the CD23 promoter was also tested alone, and in 
combinations with EBNA-2 and EBNA-3A.
The CD23 prom oter (-335/+80) has previously been shown to be 
transactivated by EBNA-2 in studies where it was cloned upstream of CAT 
and analysed in co-transfection assays with EBNA-2 in a B cell background 
(Wang, et al, 1991). Studies of the mechanism of EBNA-2 transactivation 
of the EBV TP-1 promoter have mapped an EBNA-2 responsive element (Le 
Roux, et al, 1993). Using reporter plasmids in which DNA fragments from 
the 5’ controlling region of the TP-1 promoter were positioned upstream 
of CAT and co-transfected with EBNA-2 expression vectors, it has been 
shown that an 81 bp sequence mediates the EBNA-2 transactivation effect. 
This sequence which is situated between -256 and -175 bp upstream from 
the TP-1 mRNA CAP site, contains two copies of an 11 bp sequence motif. 
Deletion of the more 5 ’ copy results in almost complete loss of EBNA-2 
responsiveness from the TP-1 promoter. This 81 bp fragm ent has also 
been shown to confer EBNA-2 responsiveness on heterologous promoters 
(Le Roux, et al, 1993).
Studies have also shown that while EBNA-3A itself has no effect on 
the TP-1 promoter, it can repress the EBNA-2-mediated transactivation in 
a B cell background (Le Roux, et al, 1994). Homologies have been shown 
between sequences present in the EBV TP-1 EBNA-2 responsive element 
and other functionally sim ilar sequences which are found in the CD23, the
EBV LMP-1 and EBNA BC-R2 promoters (Fig. 54) (Le Roux, et al, 1994).
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P rom oter Homology I Homology II
TP-1 -255 C TC GTGGGAA AAT G G -241 
-230 A CC GTGGGAA AAT A G -216
-199 C AG T G T G  -193 
-301 C AGTG T G -295
LMP-1 -290 G TT GTGGGAA GCG G C -304 
-215 G CT GTGGGAA TGC G G -229
-258 C AGTG C G -264 
-279 G AGTG C G -285
CD23 -174 C CT GTGGGAA CTT G C -160 -228 C A G T G T G  -222
BC-R2 -378 G CC GTGGGAA AAA A T -364 -355 C AGTG C G -349
Figure 54. Sequence homologies in viral and cellu lar promoter 
regions.
This indicates that the mechanism of promoter transactivation by EBNA-2 
may be s im ila r fo r at least some viral and ce llu la r prom oters, and 
EBNA-3A repression of this effect may also occur in the regulation of 
CD23 gene expression (which this study aimed to investigate and has now 
shown).
The results obtained in transfection experiments using various cell lines
will now be discussed in turn :
(A) Suspension cells.
(1) DG75 (B cell lymphoma).
The in itia l attem pts to transfect these cells used pSV2APap to 
e s ta b lish  s u c ce ss fu l e le c tro p o ra tio n  co n d itio n s . In su b se q u e n t 
transfections PAP activ ity  was detected as the transfection  contro l. 
Positive samples were subsequently assayed for CAT activity. The results 
indicate that EBNA-2 upregulates the activ ity  of the CD23 promoter, 
increasing the amount of CAT activity by a factor of 4-5 (see graphs of 
DG75 trans fec tion  assays). The EBNA-3A p ro te in  suppresses the 
EBNA-2-mediated upregulation of the CD23 promoter, with CAT activity 
returning to basal levels in the presence of both EBV proteins. The 
construct CD23CAT51 containing the deleted CD23 promoter gave no basal 
CAT activity and was not transactivated by EBNA-2. This was as expected,
as this construct contains a deletion of approx. 200 bp which should
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remove the EBNA-2 responsive elements. In assays for PAP, no PAP 
activ ity  was seen in any of the sam ples con ta in ing  the CD23PAP 
construct. As the CD23CAT plasmid produced CAT activity, it appears that 
the CD23 prom oter is active in these cells and that the CD23PAP 
construct is not functioning.
(2) HuT 78 (T cell lymphoma).
Initial attempts to transfect this cell line by e lectroporation failed. 
Using the same conditions as DG75 failed to produce any detectable PAP 
activ ity. Varying the vo ltage to 250 V (as suggested by M arianne 
Ostermann; Internet) initially produced no transfection, but when this was 
repeated, a low level of PAP was detected. The positive transfection for 
CAT produced a level of activity readily detectable by the radioassay, but 
none of the samples transfected with CD23CAT showed any detectable 
CAT. This could be due to failure of the CD23 promoter to function in these 
cells (the transfection control PAP confirm ed that the transfections had 
worked in these samples). Subsequent attempts to transfect this cell line 
have fa iled to produce any detectab le  CAT or PAP. C onditions for 
transfection need to be optim ised for this cell line, as the transfections 
so far have not been reproducible with the same set of conditions. Within 
a set of transfections, the efficiency appears to be comparable (see HuT 
78 transfection  assay set 1). However, the va ria b ility  in e ffic iency 
between batches of transfections is considerable (no transfection was 
seen in transfections set 2 or 3). Recently, it has been suggested that the 
conditions of the ce lls before trans fec tion  is c ritica l fo r optim um  
efficiency. Some groups have been using a protocol that involves feeding 
the cells every day for a week prior to transfection, keeping the cell 
density at a level of 0.5-0.6 x 106 cells/m l (Dominic Voon, Internet). This 
appears to improve transfection efficiencies.
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ÍB^ Adherent cells.
(1) Hep G2 (liver carcinoma).
These cells were transfected with pSV2APap, CMVCAT, CD23CAT +/- 
EBNA2/3A, and pG7CAT as a negative control.
During the calcium phosphate procedure, it was noted that the expected 
precipitate failed to form on the cells. This is thought to be essential for 
successful transfection to occur. When the cells were harvested and 
assayed for PAP activity, it was noted that these cells have an endogenous 
heat stable phosphatase activity. Hence all the samples were positive for 
PAP, and the results of the assay were inconclusive. The positive 
transfection contro l for CAT (sample transfected with pCMVCAT) was 
assayed for CAT activity and none was found to be present relative to a 
positive assay control (commercial CAT enzyme). It was concluded that 
the transfection failed to work in this case (probably due to the lack of 
precipitate on the cells). It may also be possible that the CMV promoter is 
not functional in this particular cell line and hence CAT expression was 
not detected. This experiment was not repeated due to the endogenous 
level of PAP activity.
(2) SW480 (colon carcinoma).
These cells proved to be very easily transfected by the calcium 
phosphate procedure, and showed a high transfection e ffic iency when 
compared to the suspension cells. The transfections were carried out 
twice. Transfection with pSV2APap gave high phosphatase activ ity which 
was easily detected in the extract after 20 minutes of incubation with the 
colorimetric substrate. The CD23Pap construct gave no activity when used 
either alone or in combination with EBNA 2/3A. This construct appears to 
be non-functional in this case. The cells were assayed fo r CAT activity 
using the phase extraction radioassay. In both sets of transfections CAT 
a c tiv ity  was de tec ted  in the p o s itive  con tro l (pC M V C A T). The 
commercially available CAT ELISA (Boehringer Mannheim) was also used to 
test these samples and the sensitiv ity of both assays was found to be 
comparable. No CAT activity was detected in the extracts from the co­
transfections with CD23CAT +/- EBNA 2/3A.
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It was concluded that the CD23 promoter may not be functional in 
these cells. A lthough identified as a B cell promoter, the basal level of 
expression in B ce lls is low unless transactiva ting  facto rs such as 
EBNA-2 are present also. However, the inclusion of these factors caused 
no detectable rise in activity of the CD23 promoter in the SW480 cells. It 
may be possible that the EBNA-2 plasmid used was not producing any 
protein. However, as this plasmid contains EBNA-2 under the control of 
the CMV promoter, and this promoter functions well in these cells (easily 
detected CAT activity from CMVCAT), this was not thought to be the case. 
A western blot using antibodies to EBNA-2 could be used to confirm the 
presence of th is protein in transfected cell extracts. It is possible that 
add itiona l ce ll-sp e c ific  fac to rs  necessary  fo r the  a c tiv ity  of th is  
promoter were absent in this case. The transfections them selves were 
working well (PAP and CAT controls) so this was not thought to be the 
problem.
The pG7CD23Pap construct appears to be non-functional in the cell 
lines so far tested. The expected sequence was constructed to ensure that 
there is no extra sequence in the polylinker that may cause problems with 
transcription and to ensure that all the PAP sequence from pSNA-APap was 
taken :
From the paper (Henthorn, et al, 1988): pSVaAPap was o rig in a lly  
constructed by taking an Eco Rl-Sca I fragment for cloning. pG7CD23Pap 
was constructed by taking an Eco Rl fragment so none of the PAP sequence 
was lost in the construction of pG7CD23Pap.
The theoretical sequence was examined in further detail to see if an ATG 
was present in the junction between CD23 and PAP:
 TCTGCTGA(Sal I repaired) (Sma l)GGGGTACC GA(Eco Rl) ATTC..........
CD23 Polylinker pGem7Zf PAP
As can be seen from above, there is no extra ATG in the polylinker or in 
the junction.
Restriction analysis of the plasm id confirm ed it had the expected 
structure. Four clones were isolated in this experiment. It may be possible 
that the clone chosen for use in the transfection assays had a mutation -
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repeating the experim ents using the other clones would e lim inate this 
p o s s ib ility .
It may be that the pG7CD23Pap construct is functional, but that the 
PAP activity produced is too low to be detected. As seen from the CAT 
assays, the basal level of CD23 promoter activity in DG75 is very low and 
the upregulation is only by a factor of 4-5. As the PAP assay appears to be 
less sensitive than the CAT assay, it is possible that even an upregulated 
PAP activity would not give a signal above the background in the enzyme 
assay. To examine if this is the case the levels of PAP mRNA before and 
after transfection could be measured to determ ine if a transactivation 
effect was occuring. It may also be the case that the novel CD23Pap mRNA 
is highly unstable.
It should be noted that this approach to promoter analysis in some 
circumstances can be limited. There may be controlling elements present 
at other locations that are missed in this analysis. For example, sequences 
that influence EBV promoter activity have previously been shown to be 
located outside the immediate 5 ’ region (Walls, et al, 1990). In some 
cases other means of gene regulation e.g. genomic methylation of coding 
sequences/promoter regions, may also be important.
In conclusion, this study has shown that in a B cell background, 
EBNA-2 transactivates the CD23 prom oter by a factor of 4-5 and this
effect is repressed by the EBNA-3A protein, which alone has no effect on
promoter activ ity. This e ffect is not seen in other cell backgrounds. 
EBNA-3A-repression of EBNA-2-mediated effects may occur in a number 
of ways. The mechanism of action of EBNA-3 may be mediated by direct 
binding of the protein to the DNA, i.e. EBNA-3 may compete with an
activation molecule e.g. CBF-1, by attaching to the CBF-1 binding site or a
site close by and hence prevent binding of e ither CBF-1 to it’s binding 
site, or binding of EBNA-2 to CBF-1. The EBNA-3 effect may also be 
mediated by protein-protein interactions, i.e. binding of EBNA-3 to either 
CBF-1 or EBNA-2 itself, could prevent EBNA-2 prom oter transactivation 
effects. Gel retardation experim ents could be carried out to investigate 
these theories in detail.
A functional antagonism between EBNA-2 and the EBNA-3 proteins 
may be im portant in the overall viral strategy. Depending on the time 
course of the ir synthesis and the am ounts of prote ins produced, the
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EBNA-3 proteins may offer a means to regulate EBNA-2 transactivating 
functions in a qualitative and/or quantitative manner. Previous studies 
have shown that EBNA-2 is the first protein to be expressed, with EBNA-3 
appearing later. EBNA-2 is necessary for im mortalisation to occur, but is 
not required to maintain the im mortalised state, and may have effects 
that are tox ic to the cell if prolonged e.g. EBNA-2 upregulates the 
expression of LMP which when over-expressed can be toxic to the cell 
(H a m m e rs c h m id t,  et al, 1989). Thus EBNA-3 may repress EBNA-2- 
mediated effects, ensuring survival of the EBV-infected cell in vivo .
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